<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">60352</article-id><article-id pub-id-type="doi">10.7554/eLife.60352</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Computational and Systems Biology</subject></subj-group></article-categories><title-group><article-title>A statistical framework for assessing pharmacological responses and biomarkers using uncertainty estimates</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-194406"><name><surname>Wang</surname><given-names>Dennis</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0068-1005</contrib-id><email>dennis.wang@sheffield.ac.uk</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-195720"><name><surname>Hensman</surname><given-names>James</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-194408"><name><surname>Kutkaite</surname><given-names>Ginte</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2918-294X</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-194409"><name><surname>Toh</surname><given-names>Tzen S</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4211-333X</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-215567"><name><surname>Galhoz</surname><given-names>Ana</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7402-5292</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><collab>GDSC Screening Team<contrib-group><contrib contrib-type="author"><name><surname>Lightfoot</surname><given-names>Howard</given-names></name></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Wanjuan</given-names></name></contrib><contrib contrib-type="author"><name><surname>Soleimani</surname><given-names>Maryam</given-names></name></contrib><contrib contrib-type="author"><name><surname>Barthorpe</surname><given-names>Syd</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mironenko</surname><given-names>Tatiana</given-names></name></contrib><contrib contrib-type="author"><name><surname>Beck</surname><given-names>Alexandra</given-names></name></contrib><contrib contrib-type="author"><name><surname>Richardson</surname><given-names>Laura</given-names></name></contrib><contrib contrib-type="author"><name><surname>Lleshi</surname><given-names>Ermira</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hall</surname><given-names>James</given-names></name></contrib><contrib contrib-type="author"><name><surname>Tolley</surname><given-names>Charlotte</given-names></name></contrib><contrib contrib-type="author"><name><surname>Barendt</surname><given-names>William</given-names></name></contrib></contrib-group></collab><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con6"/></contrib><contrib contrib-type="author" id="author-160794"><name><surname>Dry</surname><given-names>Jonathan R</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-156760"><name><surname>Saez-Rodriguez</surname><given-names>Julio</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8552-8976</contrib-id><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-194411"><name><surname>Garnett</surname><given-names>Mathew J</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-148072"><name><surname>Menden</surname><given-names>Michael P</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0267-5792</contrib-id><email>michael.menden@helmholtz-muenchen.de</email><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-194405"><name><surname>Dondelinger</surname><given-names>Frank</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1816-6300</contrib-id><email>fdondelinger.work@gmail.com</email><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf4"/></contrib><aff id="aff1"><label>1</label><institution>Sheffield Institute for Translational Neuroscience, University of Sheffield</institution><addr-line><named-content content-type="city">Sheffield</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff2"><label>2</label><institution>Department of Computer Science, University of Sheffield</institution><addr-line><named-content content-type="city">Sheffield</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff3"><label>3</label><institution>PROWLER.io</institution><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff4"><label>4</label><institution>Institute of Computational Biology, Helmholtz Zentrum München—German Research Center for Environmental Health</institution><addr-line><named-content content-type="city">Neuherberg</named-content></addr-line><country>Germany</country></aff><aff id="aff5"><label>5</label><institution>Department of Biology, Ludwig-Maximilians University Munich</institution><addr-line><named-content content-type="city">Martinsried</named-content></addr-line><country>Germany</country></aff><aff id="aff6"><label>6</label><institution>The Medical School, University of Sheffield</institution><addr-line><named-content content-type="city">Sheffield</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff7"><label>7</label><institution>Wellcome Sanger Institute</institution><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff8"><label>8</label><institution>Research and Early Development, Oncology R&amp;D, AstraZeneca</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff9"><label>9</label><institution>Institute of Computational Biomedicine,Faculty of Medicine,Heidelberg Universityand Heidelberg University Hospital, Bioquant</institution><addr-line><named-content content-type="city">Heidelberg</named-content></addr-line><country>Germany</country></aff><aff id="aff10"><label>10</label><institution>German Center for Diabetes Research (DZD e.V.)</institution><addr-line><named-content content-type="city">Neuherberg</named-content></addr-line><country>Germany</country></aff><aff id="aff11"><label>11</label><institution>Centre for Health Informatics, Computation and Statistics, Lancaster Medical School, Lancaster University</institution><addr-line><named-content content-type="city">Lancaster</named-content></addr-line><country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Lehár</surname><given-names>Joseph</given-names></name><role>Reviewing Editor</role><aff><institution>Boyce Thompson Institute for Plant Research</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Weigel</surname><given-names>Detlef</given-names></name><role>Senior Editor</role><aff><institution>Max Planck Institute for Developmental Biology</institution><country>Germany</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>04</day><month>12</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>9</volume><elocation-id>e60352</elocation-id><history><date date-type="received" iso-8601-date="2020-06-24"><day>24</day><month>06</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-12-04"><day>04</day><month>12</month><year>2020</year></date></history><permissions><copyright-statement>© 2020, Wang et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Wang et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-60352-v3.pdf"/><abstract><p>High-throughput testing of drugs across molecular-characterised cell lines can identify candidate treatments and discover biomarkers. However, the cells’ response to a drug is typically quantified by a summary statistic from a best-fit dose-response curve, whilst neglecting the uncertainty of the curve fit and the potential variability in the raw readouts. Here, we model the experimental variance using Gaussian Processes, and subsequently, leverage uncertainty estimates to identify associated biomarkers with a new Bayesian framework. Applied to in vitro screening data on 265 compounds across 1074 cancer cell lines, our models identified 24 clinically established drug-response biomarkers, and provided evidence for six novel biomarkers by accounting for association with low uncertainty. We validated our uncertainty estimates with an additional drug screen of 26 drugs, 10 cell lines with 8 to 9 replicates. Our method is applicable to any dose-response data without replicates, and improves biomarker discovery for precision medicine.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>pharmacogenomics</kwd><kwd>biomarkers</kwd><kwd>machine learning</kwd><kwd>drug prediction</kwd><kwd>statistical inference</kwd><kwd>uncertainty estimation</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution>NIHR Sheffield Biomedical Research Centre</institution></institution-wrap></funding-source><award-id>BRC - IS-BRC-1215-20017</award-id><principal-award-recipient><name><surname>Wang</surname><given-names>Dennis</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000833</institution-id><institution>Rosetrees Trust</institution></institution-wrap></funding-source><award-id>A2501</award-id><principal-award-recipient><name><surname>Wang</surname><given-names>Dennis</given-names></name><name><surname>Toh</surname><given-names>Tzen S</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000691</institution-id><institution>Academy of Medical Sciences</institution></institution-wrap></funding-source><award-id>SBF004/1052</award-id><principal-award-recipient><name><surname>Wang</surname><given-names>Dennis</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004440</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source><award-id>206194</award-id><principal-award-recipient><name><surname>Garnett</surname><given-names>Mathew J</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100007601</institution-id><institution>Horizon 2020 - Research and Innovation Framework Programme</institution></institution-wrap></funding-source><award-id><italic>Grant agreement No.</italic> 950293 - COMBAT-RES</award-id><principal-award-recipient><name><surname>Menden</surname><given-names>Michael P</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Quantification of uncertainty in drug dose-responses provides a more robust metric for differentiating drugs and identifying biomarkers of response.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The failure rate for new drugs entering clinical trials is in excess of 90%, with more than a quarter of drugs failing due to lack of efficacy (<xref ref-type="bibr" rid="bib1">Arrowsmith and Miller, 2013</xref>; <xref ref-type="bibr" rid="bib6">Cook et al., 2014</xref>). The rapid development of technologies for deep molecular characterisation of clinical samples holds the promise to uncover molecular biomarkers that stratify patients towards more efficacious drugs, a cornerstone of precision medicine. In oncology, we can identify potential biomarkers of drug response in high-throughput screens (HTS) of patient-derived cell lines; these biomarkers need to be then validated in patients.</p><p>Assessment of cell line drug response typically involves treatment with multiple concentrations of the compound, followed by measurement of the amount of viable cells after a fixed period of time for each dose, and derivation of a dose-response curve. The drug response is commonly then summarised by measurements taken from this curve, most often the concentration required to reduce cell viability by half that is IC<sub>50</sub>, or the area under the curve that is AUC. Currently the two largest in vitro drug screening studies, the Genomics of Drug Sensitivity in Cancer (GDSC) (<xref ref-type="bibr" rid="bib14">Garnett et al., 2012</xref>; <xref ref-type="bibr" rid="bib23">Iorio et al., 2016</xref>) and the Cancer Therapeutics Response Portal (CTRP) <xref ref-type="bibr" rid="bib38">Rees et al., 2016</xref> have shown that some clinically-actionable biomarkers of drug response can be concordantly discovered (<xref ref-type="bibr" rid="bib23">Iorio et al., 2016</xref>; <xref ref-type="bibr" rid="bib40">Seashore-Ludlow et al., 2015</xref>), and that different properties and mechanisms of drug response are best captured by different metrics dependent on the dose-response curve (<xref ref-type="bibr" rid="bib12">Fallahi-Sichani et al., 2013</xref>).</p><p>Most HTS efforts focus on increasing throughput (<xref ref-type="bibr" rid="bib23">Iorio et al., 2016</xref>; <xref ref-type="bibr" rid="bib40">Seashore-Ludlow et al., 2015</xref>) and thereby often neglect experimental replicates, which renders it impossible to correct for experimental noise, resulting in uncertainty for the estimated drug-response metrics (e.g. IC<sub>50</sub> value). Extrapolating IC<sub>50</sub> values beyond the tested drug concentration range is particularly challenging and often unaccounted for in quality control metrics (<xref ref-type="bibr" rid="bib17">Haibe-Kains et al., 2013</xref>; <xref ref-type="bibr" rid="bib18">Haverty et al., 2016</xref>). Most published studies using machine learning algorithms or mechanistic models for predicting drug response and biomarkers assume that the measured drug responses are precise (<xref ref-type="bibr" rid="bib8">Costello et al., 2014</xref>; <xref ref-type="bibr" rid="bib25">Keshava et al., 2019</xref>; <xref ref-type="bibr" rid="bib33">Menden et al., 2019</xref>; <xref ref-type="bibr" rid="bib42">Silverbush et al., 2017</xref>). If this assumption is not met and there is high uncertainty in the measured drug-response values, the utility of these methods for enhancing drug development may be severely limited (<xref ref-type="bibr" rid="bib8">Costello et al., 2014</xref>; <xref ref-type="bibr" rid="bib33">Menden et al., 2019</xref>; <xref ref-type="bibr" rid="bib42">Silverbush et al., 2017</xref>). Experimental noise can be reduced by adding experimental replicates, however, this either reduces the throughput of the screen or increases the cost. Most current models for curve fitting and describing dose-response data have primarily assumed that cell viability has a sigmoidal relationship to the logarithm of the dose concentrations of the drug (<xref ref-type="bibr" rid="bib9">Dawson et al., 2012</xref>; <xref ref-type="bibr" rid="bib51">Wang et al., 2010</xref>). Whilst some models are more flexible by allowing many inflection points in the dose-response curve (<xref ref-type="bibr" rid="bib10">Di Veroli et al., 2016</xref>; <xref ref-type="bibr" rid="bib49">Vis et al., 2016</xref>), their main output is a single drug-response value that does not fully capture the uncertainty in the measurements (<xref ref-type="bibr" rid="bib12">Fallahi-Sichani et al., 2013</xref>).</p><p>Gaussian Processes (GP) are a flexible, probabilistic modelling technique that has been successfully used to measure uncertainty in noisy gene expression datasets (<xref ref-type="bibr" rid="bib28">Lopez-Lopera and Alvarez, 2019</xref>) and has been incorporated into machine learning prediction of cell fates (<xref ref-type="bibr" rid="bib2">Boukouvalas et al., 2018</xref>). This technique has been shown to cope well with regression tasks on dependent data and high dimensional covariates (<xref ref-type="bibr" rid="bib37">Rasmussen and Williams, 2005</xref>; <xref ref-type="bibr" rid="bib41">Shi and Choi, 2011</xref>). Instead of fitting a single function to the data, GPs allow for a flexible range of beliefs about the function underlying the data (<xref ref-type="bibr" rid="bib47">Tian et al., 2017</xref>). In the case of cell line drug responses, this can be conceptualised as fitting a range of curves that have equivalently strong fit to the data. We can sample from the inferred posterior distribution over functions, that is the variance between these curves, to generate uncertainty estimates of quantities of interest, in our case, properties of the dose-response such as IC<sub>50</sub>.</p><p>GPs have been recently utilised to identify and guide experimental validation of compounds, on top of being applied to protein engineering and imputing gene expression values (<xref ref-type="bibr" rid="bib20">Hie et al., 2020</xref>). GPs have also been used in conjunction with neural networks to model dose-response curves as a function of molecular markers (<xref ref-type="bibr" rid="bib45">Tansey et al., 2018</xref>). The main objective in this work was to predict drug response using the molecular measurements, and the non-linear nature of the prediction model makes interpretation for the purpose of biomarker detection challenging. By contrast, we aimed to develop a model that could provide interpretable summary statistics with uncertainty estimates that can be flexibly used to improve biomarker detection.</p><p>In this study, we therefore introduce a new GP regression approach for describing dose-response relationships in cancer cell lines that quantifies the uncertainty of the model fitted to measured responses for each single experiment, and we show that estimates of IC<sub>50</sub> values within the tested concentration range correlates with confidence intervals obtained experimentally from replicate experiments. Subsequently, we use our new dose-response model to identify genetic sensitivity and resistance biomarkers in standard statistical tests (e.g. ANOVA). We demonstrate how the flexibility of the GP dose-response modelling can be further exploited in a Bayesian framework to identify novel biomarkers. We also describe the variation in the level of drug response uncertainty across cancer types and drug classes. By accounting for the uncertainty in dose-response experiments, detection of clinically-actionable biomarkers can be enhanced.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>A probabilistic framework for measuring dose-response and predicting biomarkers</title><p>We analysed in vitro screening data on 265 compounds across 1,074 cell lines (<xref ref-type="bibr" rid="bib23">Iorio et al., 2016</xref>). In those experiments, we quantified the amount of cytotoxicity after four days of compound treatments at each dose compared to controls (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). The relationship between the dose and response (decrease in cell viability) was first described using a dose-response curve derived with a sigmoidal function (<xref ref-type="fig" rid="fig1">Figure 1B and C</xref>). This assumes that the number of viable cells decreases at an exponential rate, then slows down and eventually plateaus at a lower limit. Since it was costly to test all possible doses, the sigmoid function was used to extrapolate the response at concentrations that had not been tested and to estimate overall measures of response, such as IC<sub>50</sub> or AUC values, for downstream analysis. However, considering that each experiment tested only between five and nine dosage concentrations per experiment in GDSC, and a maximum of 16 in CTRP, the tightness of fit of the dose-response curve to the data points and therefore the level of uncertainty about the inferred response may vary. We utilised the probabilistic nature of GP models to quantify the uncertainty in the dose-response experiments as an alternate approach (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). We sampled from the fitted GP and used the posterior distribution to quantify the uncertainty in curve fits for each experiment. We again generated summary statistics, IC<sub>50</sub> and AUC values, by taking the average of the GP samples and also quantified the level of uncertainty for these statistics (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). The GP model has the advantage that it models outliers at higher doses as one component of a two-component Beta mixture in the model (see Materials and methods). Such outliers are typically the result of an experimental failure, and cannot be modelled using simple Gaussian noise without over-estimating the noise parameter.</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Workflow for fitting of Gaussian Process models to dose-response curves and estimating their uncertainty.</title><p>(<bold>A</bold>) Large-scale drug screens test cell lines with different drugs and at different doses are used to obtain dose-response data. (<bold>B</bold>) Typically, for each drug tested in a cell line, the sigmoid model is fit to the drug-response data and (<bold>C</bold>) the overall measures of response (IC<sub>50</sub>, AUC, etc.) are extracted. (<bold>D</bold>) For each drug tested in a cell line, we fit a GP model to the dose-response data. The GP allows us to sample from a distribution of possible dose-response curves, obtaining a measure of uncertainty. (<bold>E</bold>) From these curves, we can extract overall measures of response, such as IC<sub>50</sub>, and importantly, their 95% confidence intervals. (<bold>F</bold>) Mutation markers for each cell line can be determined based on presence/absence of single nucleotide polymorphisms (SNPs) in key genes. Both the drug-response estimates and the mutation markers are used to compute (<bold>G</bold>) the F-statistic for ANOVA, and (<bold>H</bold>) Bayesian test for biomarker association. The drug-response summary measure g<sub>i</sub> for cell line i is modelled via a cell line- specific mean µ<sub>i </sub>and standard error σ<sub>i</sub>. The mean is defined as a linear effect β of the biomarker status z<sub>i </sub>and a further effect γ from any remaining covariates x<sub>i</sub>, such as tissue type. The parameter σ* is the standard deviation of µ<sub>i</sub>. (<bold>I</bold>) Boxplots illustrate the differences in the estimated mean IC<sub>50</sub> of <italic>ERBB2</italic> amplified and non-amplified breast cancer cell lines treated with afatinib. An ANOVA test was used to test this difference in means but did not consider uncertainty in each IC<sub>50</sub> estimate. (<bold>J</bold>) We estimated posterior distributions of gene association using the Bayesian model, that is the effect of a genetic mutation on the IC<sub>50</sub> measurement of drug response. Distributions centred on zero indicate no effect whilst distributions on either side of zero indicate positive or negative effects of mutations on drug response.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60352-fig1-v3.tif"/></fig><p>After fitting the dose-response data using the sigmoid and GP models, we tested various biomarker hypotheses by examining the association between the overall response statistics from the models with genetic variants detected in the cell lines using a frequentist and a Bayesian approach (<xref ref-type="fig" rid="fig1">Figure 1F–H</xref>). For one biomarker hypothesis, as an example, we examined copy number alterations and point mutations in breast cancer cell lines in relation to the measured drug response of afatinib in those cells. The GP and sigmoid estimated IC<sub>50</sub> from cell lines treated with afatinib were significantly different in cases with and without <italic>ERBB2</italic> amplification (ANOVA q-value = 4.12e-9; <xref ref-type="fig" rid="fig1">Figure 1I</xref>). The GP models provided an added benefit of providing uncertainty estimates that were incorporated into a Bayesian hierarchical model to further verify the association between <italic>ERBB2</italic> amplification and afatinib sensitivity (posterior probability = 0.001; <xref ref-type="fig" rid="fig1">Figure 1J</xref>).</p></sec><sec id="s2-2"><title>Gaussian Processes provide estimates of dose-response uncertainty for single experiments</title><p>Both GP and sigmoid curve fitting produced comparable IC<sub>50</sub> and AUC estimates. Precursor sigmoid curve fitting methods based on Markov Chain Monte Carlo simulations enabled error estimates in IC<sub>50</sub> values (<xref ref-type="bibr" rid="bib14">Garnett et al., 2012</xref>), however, this was neglected in the state-of-the-art sigmoid curve fitting (<xref ref-type="bibr" rid="bib49">Vis et al., 2016</xref>) due to missing propagation to biomarker identification. Here, we introduce the added benefit of sampling from the GP posterior, which provides the models in-build uncertainty obtained for these IC<sub>50</sub> estimates. This is important for high-throughput drug screening experiments where there is often a high number of drugs and samples tested but very few replicate experiments. By applying the GP model to each experiment, we estimated the standard deviation for each IC<sub>50</sub> or AUC value based only on data points from that single experiment. These single sample standard deviations were compared to the standard deviations measured from here provided replicate experiments, that is the same drug tested multiple times on the same cell line and at the same concentration. We applied our GP estimation method to data from replicate experiments of 26 drugs on 10 cell lines, which contained 260 test conditions and 8 to 9 replicates for each condition. We wanted to see if an estimate of the uncertainty of the summary statistic, such as the standard deviation of the IC<sub>50</sub> posterior samples, would be correlated with the dispersion between replicates. Here, we refer to the variability between (mean) estimates for replicates as the observation uncertainty, and the variability in the estimate for a single replicate as the estimation uncertainty.</p><p>We compared observation and estimation uncertainty across replicate experiments of all 260 conditions (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). When the estimation uncertainty is large, we will have less confidence in the estimated IC<sub>50</sub> in an experiment. Measurement errors for individual points in a dose-response curve will generally result in larger estimation uncertainty, whereas greater variation between biological replicates will result in larger observation uncertainty. We found two trends in the relationship between observation and estimation uncertainty. First, for experiments where the estimated IC<sub>50</sub> lies within the concentration range tested, the estimation uncertainty is positively correlated (Pearson correlation = 0.84, 95% CI [0.76, 0.89]) with the observation uncertainty. Second, for experiments where the estimated IC<sub>50</sub> lies beyond the maximum tested concentration, we observed a negative correlation (Pearson correlation = −0.39, 95% CI [−0.51,–0.25]). We note that the latter experiments require extrapolation to estimate the IC<sub>50</sub> beyond the concentration range, which increases the estimation uncertainty, but does not generally affect the observational uncertainty. However, we observed that the estimation uncertainty from our GPs for dabrafenib (BRAF inhibitor) tested in two independent studies on the same cell lines were comparable both within and beyond the concentration range (<xref ref-type="fig" rid="fig2">Figure 2B</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Comparison of GP estimates of uncertainty to replicate drug screening experiments.</title><p>(<bold>A</bold>) Comparison between observational uncertainty (standard deviation over replicates of log10(IC<sub>50</sub>) mean estimates) and estimation uncertainty (average over replicates of log10(IC<sub>50</sub>) standard deviation) from each replication experiment. The colour of the points indicates whether the log10(IC<sub>50</sub>) mean estimates were within or outside the maximum concentration range for each assay. (<bold>B</bold>) Mean IC<sub>50</sub> and the estimation uncertainty from the GPs for a BRAF inhibitor (dabrafenib) tested in each cell line in two independent studies (GDSC and CTD2). Estimation uncertainty (error bars and grey shading) were larger beyond the max concentration in both GDSC (dashed line) and CTD2 (grey line). The point estimates of the IC<sub>50</sub>s from the GPs (black dots) were also comparable to the published IC<sub>50</sub>s (red dots). (<bold>C-E</bold>) Three sets of replicate experiments, representing different amounts of estimation and observation uncertainty. Each density represents the distribution of IC<sub>50</sub> values from the Gaussian process samples from each replicate experiment. The colours represent different experimental batches. Narrow distributions demonstrate low estimation uncertainty and overlapping distributions demonstrate low observation uncertainty. The thick black line represents the density obtained by pooling samples from all replicates and the dashed line shows the maximal dosage tested. GP-curve fits corresponding to the three sets of replicate experiments showing IC<sub>50</sub> estimates with (<bold>F</bold>) high uncertainty, (<bold>G</bold>) low uncertainty, and (<bold>H</bold>) mix of uncertainties depending on whether estimates are made within or beyond the max concentration. The blue areas represent the 95% confidence interval in the curve fits and extrapolated GP curves (light grey lines) are displayed up to five times the maximum concentration, where the uncertainty will be extremely high.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60352-fig2-v3.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Investigation of batch effects in the replicate data.</title><p>Scatterplot of observation uncertainty against average estimation uncertainty, split by experimental batch.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60352-fig2-figsupp1-v3.tif"/></fig></fig-group><p>Since the replicate experiments were conducted in batches over a period of several months, we verified that the observed trends held regardless of batches (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). Additionally, we examined the relationship between estimation uncertainty and observation uncertainty in a number of edge cases where IC<sub>50</sub> was estimated within and beyond the maximum concentration tested (<xref ref-type="fig" rid="fig2">Figure 2C–E</xref>). In the case of olaparib tested on PC-14, the uncertainty for the IC<sub>50</sub> within each replicate experiment was high, and this level of uncertainty was consistent across all replicates even beyond the max concentration (<xref ref-type="fig" rid="fig2">Figure 2C and F</xref>). In other replicate experiments, both estimation and observation uncertainty were low (<xref ref-type="fig" rid="fig2">Figure 2D and G</xref>), or varied depending on whether the batch reported mostly IC<sub>50</sub> values beyond the concentration range. Talazoparib tested in colorectal cancer line HCT-15 is a case where observation uncertainty was high, even though estimation uncertainty was low, and experiments in different batches showed different estimated IC<sub>50</sub>s from very different dose-response curves (<xref ref-type="fig" rid="fig2">Figure 2E and H</xref>).</p><p>In order to examine the diversity of uncertainty estimates across experiments further, we described the relationship between AUC value of GP fits with their corresponding estimation uncertainty (<xref ref-type="fig" rid="fig3">Figure 3</xref>). We decided to use AUC here due to the greater uncertainty of estimating IC<sub>50</sub>s beyond the maximum dose concentration. Since AUCs were computed within the tested concentration range, the estimation uncertainty for AUC was not substantially higher for cases where IC<sub>50</sub>s were estimated within compared to beyond the maximum concentration (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). The difference between the AUC estimates from the GP compared to the published GDSC sigmoid curve fits was greatest for experiments showing a partial response (AUC between 0.4 and 0.9), whilst at the same time these experiments also had the highest estimation uncertainty (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Our visual examination of the raw dose-response data from those experiments revealed evidence of poor quality readouts, for instance, where cell viability increases with increasing drug dose (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). We were able to quantify the quality of these readouts by estimating the Spearman correlation coefficient based on the raw cell viability counts and the dose concentrations (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). A negative Spearman correlation indicates that cell viability decreases as dosage increases (as expected) whilst a positive Spearman correlation indicates the opposite. The experiments with high estimation uncertainty from our GPs were also the experiments with high Spearman correlation pointing to poor quality.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Relationship between AUC and uncertainties estimated from GPs across all experiments.</title><p>(<bold>A</bold>) Coloured by difference between the AUC estimated by sigmoid vs GP fits. (<bold>B</bold>) Coloured by Spearman correlation between cell viability and dose concentration in the raw data. Poorer experiments (orange-red) result in greater uncertainty and positively correlated with cell viability increasing with higher dose. (<bold>C</bold>) Average uncertainty and AUC for experiments with uncertain fits (estimation uncertainty &gt;0.03) with drugs grouped by their target pathway. (<bold>D</bold>) Distribution of estimation uncertainty for all drugs targeting chromatin histone methylation, chromatin histone acetylation, and mitosis and (<bold>E</bold>) for individual drugs.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60352-fig3-v3.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>High estimation uncertainty independent of concentration range.</title><p>(<bold>A</bold>) Estimation uncertainty for AUC (standard deviation) across replicate experiments were robust to whether the IC<sub>50</sub> was within or beyond the maximum concentration tested. (<bold>B</bold>) Dose- response of a single experiment where there was high estimation uncertainty (dotted red line) despite the fitted curve (red line) crossing 50% viable cells before reaching the max dose concentration (dotted green line). The probability distribution of IC<sub>50</sub> is estimated across dose concentrations (solid green line), however, raw data points (red dots) show increased cell viability with increased dose.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60352-fig3-figsupp1-v3.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Relationship between uncertainties and other experimental factors.</title><p>Estimation uncertainty grouped by (<bold>A</bold>) cancer type of cell lines, (<bold>B</bold>) growth media used, (<bold>C</bold>) tissue of origin, (<bold>D</bold>) growth condition of the cells, (<bold>E</bold>) dilution factor for each dose tested of a drug, and (<bold>F</bold>) target pathways of drugs.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60352-fig3-figsupp2-v3.tif"/></fig></fig-group><p>Next, we investigated whether there were any attributes of experiments that would correspond to high estimation uncertainty and poor quality results. Labelling of experiments based on cell culture conditions, dose and cancer type revealed no obvious associations with estimation uncertainty (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2A–E</xref>). However, there was a large spread in the uncertainty estimates for AUC when we grouped the experiments into target pathways based on the primary targets of the tested drugs (<xref ref-type="fig" rid="fig3">Figure 3C</xref>; <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2F</xref>). Whilst most drugs had similar average AUC point estimates between 0.6 and 0.8, suggesting they all had a spread of experiments showing resistance and sensitivity, the average estimation uncertainties varied across target pathways. Interestingly, similar target pathways (e.g. chromatin histone methylation and chromatin histone acetylation) had very different levels of estimation uncertainty. Within each of these target pathways, we also see different distributions of estimation uncertainties (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). Most target pathways have a bi-modal distribution representing compounds that have low uncertainty in the cases of clear sensitivity or resistance, and high uncertainty in the cases of partial responders (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). Both chromatin histone methylation drugs in particular had a much longer right tail towards higher estimation uncertainties that are associated with poor experimental readouts, or possibly off-targets.</p></sec><sec id="s2-3"><title>Curve fits using Gaussian Processes can help identify clinically relevant biomarkers</title><p>The IC<sub>50</sub> values are highly conconcordant for sigmoid and GP-curve fittings, showing an average weighted Pearson correlation of 0.88 (95% CI [0.85; 0.91]) across individual drugs, and cancer types (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Strong agreement is found when true responding cell lines were observed in the screen (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). For example, if &gt;10% of cell lines responded within the concentration range, that is IC<sub>50</sub> &lt;maximum tested concentration, then a weighted Pearson correlation &gt;0.75 was consistently achieved for all drugs. We found positive correlations for all drugs, even when comparing exclusively non-responding cell lines, where all the IC<sub>50</sub> values are extrapolated beyond the maximum dosage range. Drug-response values are concordantly fitted with both methods for sensitive cell lines (<xref ref-type="fig" rid="fig4">Figure 4C</xref>, mean log10(IC<sub>50</sub>) in µM of 0.02 95% CI [−0.05; 0.09]), whilst extrapolated non-responders tend to lead to more conservative and higher IC<sub>50</sub> values fitted with GP (<xref ref-type="fig" rid="fig4">Figure 4C</xref>, mean log10(IC<sub>50</sub>) in µM of 1.10, 95% CI [1.03; 1.18]). Whilst the average fits from the sigmoid and GP models identify known clinical biomarkers, there are clearly differences for individual cell lines, especially when the IC<sub>50</sub> value has been extrapolated beyond the dosage range, that may help identify new biomarkers. Alternatively, AUC values can be used to compare both curve fitting methods (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). Whilst known clinical biomarkers are recovered with AUC as a drug-response metric, IC<sub>50</sub> measures were used in the subsequent analysis as they retain direct relationship with the drug concentration and are more interpretable.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Comparison of sigmoid and GP-curve fitting.</title><p>(<bold>A</bold>) Weighted Pearson correlation of each drug within cancer types. (<bold>B</bold>) Comparing the concordance of sigmoid and GP-curve fitting when stratifying for percentage of cell lines with IC<sub>50</sub> value lower than maximum concentration. (<bold>C</bold>) IC<sub>50</sub> value difference between GP and sigmoid curves. Grey histogram represents frequency distribution of the IC<sub>50</sub> value difference between GP and sigmoid curves without stratification by within/outside the concentration range. (<bold>D</bold>) Drug-response biomarker comparison based on both curve fittings (sigmoid vs GP). The Benjamini-Hochberg adjusted p-values are in log10 scale and signed based on the direction of the effect size (Cohen’s d). Additional biomarker examples for (<bold>E</bold>) diffuse large B-cell lymphoma (DLBCL) treated with nutlin-3a (MDM2 inhibitor) and stratified by <italic>TP53</italic> mutants; (<bold>F</bold>) Low grade glioma (LGG) treated with daporinad (NAMPT inhibitor) and stratified by <italic>EGFR</italic> amplification; (<bold>G</bold>) Skin cutaneous melanoma (SKCM) treated with doramapimod (p38 and JNK2 inhibitor) and stratified with <italic>ARID2</italic> mutations.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60352-fig4-v3.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Comparison of GP and Sigmoid curve fitting using AUCs.</title><p>GP fitted log10(IC50)s with standard error (grey error bars) of the cell lines treated with (<bold>A</bold>) Lapatinib and (<bold>B</bold>) Nutlin-3a. GP fitted AUCs with standard error (grey error bars) of the cell lines treated with (<bold>C</bold>) Lapatinib and (<bold>D</bold>) Nutlin-3a. Volcano plot of drug-response biomarker associations based on (<bold>E</bold>) sigmoid and (<bold>F</bold>) GP-curve fitting using AUC as a measure. (<bold>G</bold>) Drug-response biomarker comparison based on both curve fittings.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60352-fig4-figsupp1-v3.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Comparison of sigmoid and GP-curve fitting using IC<sub>50</sub>s.</title><p>Volcano plot of drug-response biomarker associations based on (<bold>A</bold>) sigmoid and (<bold>B</bold>) GP-curve fitting. (<bold>C</bold>) Drug-response biomarker comparison based on both curve fittings, and colour coding percentage of drug-response data observed within- concentration range.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60352-fig4-figsupp2-v3.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>Drug-response biomarker comparison based on both curve fittings.</title><p>Dashed line depicts maximum concentration. (<bold>A</bold>) Skin cutaneous melanoma (SKCM) treated with PLX-4720 (BRAF inhibitor) and stratified with <italic>BRAF</italic> mutations; (<bold>B</bold>) Skin cutaneous melanoma (SKCM) treated with PLX-4720 (BRAF inhibitor) and stratified with <italic>BRAF</italic> mutations - replicate; (<bold>C</bold>) Skin cutaneous melanoma (SKCM) treated with Dabrafenib (BRAF inhibitor) and stratified with <italic>BRAF</italic> mutations; (<bold>D</bold>) Thyroid carcinoma (THCA) treated with Dabrafenib (BRAF inhibitor) and stratified with <italic>BRAF</italic> mutations; (<bold>E</bold>) Lung adenocarcinoma (LUAD) treated with Afatinib (ERBB2, EGFR inhibitor) and stratified with <italic>EGFR</italic> mutations; (<bold>F</bold>) Lung adenocarcinoma (LUAD) treated with Afatinib (ERBB2, EGFR inhibitor) and stratified with <italic>EGFR</italic> mutations - replicate; (<bold>G</bold>) Lung adenocarcinoma (LUAD) treated with Gefitinib (EGFR inhibitor) and stratified with <italic>EGFR</italic> mutations; (<bold>H</bold>) Breast invasive carcinoma (BRCA) treated with Lapatinib (ERBB2, EGFR inhibitor) and stratified with <italic>ERBB2</italic> amplifications; (<bold>I</bold>) Acute Myeloid Leukemia (LAML) treated with nutlin-3a (MDM2 inhibitor) and stratified by <italic>TP53</italic> mutants; (<bold>J</bold>) Ovarian serous cystadenocarcinoma (OV) treated with nutlin-3a (MDM2 inhibitor) and stratified by <italic>TP53</italic> mutants; (<bold>K</bold>) Glioblastoma multiforme (GBM) treated with nutlin-3a (MDM2 inhibitor) and stratified by <italic>TP53</italic> mutants; (<bold>L</bold>) Skin cutaneous melanoma (SKCM) treated with nutlin-3a (MDM2 inhibitor) and stratified by <italic>TP53</italic> mutants.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60352-fig4-figsupp3-v3.tif"/></fig></fig-group><p>To highlight the overall agreement of both curve fitting methods, we systematically tested 26 clinically established biomarkers of drug response (<xref ref-type="fig" rid="fig4">Figure 4D</xref>, <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A–C</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>) using previously established association tests (<xref ref-type="bibr" rid="bib23">Iorio et al., 2016</xref>), 24 of which were significantly reproduced regardless of sigmoid or GP-curve fitting (10% FDR). For example, both curve fittings captured the association of BRAF inhibitors (PLX4720, progenitor of vemurafenib; and dabrafenib) with <italic>BRAF</italic> mutations in melanoma (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3A–C</xref>; <xref ref-type="bibr" rid="bib4">Chapman et al., 2011</xref>). Dabrafenib is a potent BRAF inhibitor and in addition we detected <italic>BRAF</italic> mutations as a sensitivity marker in thyroid carcinoma (<xref ref-type="fig" rid="fig4">Figure 4D</xref>, <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3D</xref>). Another example are the EGFR inhibitors, afatinib and gefitinib, that are concordantly correlated with drug sensitivity in <italic>EGFR</italic> mutant cell lines in lung adenocarcinoma (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3E–G</xref>; <xref ref-type="bibr" rid="bib44">Tamura and Fukuoka, 2005</xref>; <xref ref-type="bibr" rid="bib52">Yang et al., 2012</xref>). <italic>ERBB2</italic>(<italic>HER2</italic>) amplification in breast cancer was also recapitulated as a biomarker of sensitivity to the dual EGFR/ERBB2 inhibitor lapatinib (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3H</xref>; <xref ref-type="bibr" rid="bib26">Konecny et al., 2006</xref>). Among the 26 clinical biomarkers, we consistently found drug resistance of <italic>TP53</italic> mutants to MDM2 inhibition with nutlin-3a in five different cancer types (<xref ref-type="fig" rid="fig4">Figure 4E</xref>, <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3I–L</xref>). Overall, the majority of expected clinical and preclinical biomarkers are reproduced, regardless of the drug-response curve fitting method.</p><p>We concordantly and significantly identified six novel (not yet clinically established) drug sensitivity biomarkers (0.1% FDR) regardless of the applied drug-response curve fitting method. Investigating two different curve fitting algorithms, and retrieving the same biomarkers can be considered as a test of robustness, which in our case concordantly highlighted non-gold standard associations for prioritising experimental validation. For example, daporinad (also known as FK866 and APO866) is a small-molecule inhibitor of nicotinamide phosphoribosyltransferase leading to inhibition of NAD+ biosynthesis. It has been clinically tested in melanoma (<ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> Identifier: NCT00432107), Refractory B-CLL (NCT00435084) and Cutaneous T-cell Lymphoma (NCT00431912), whilst showing anti-proliferative effect in glioblastoma cell lines (<xref ref-type="bibr" rid="bib54">Zhang et al., 2012</xref>). Therapeutic potential when combining with other drugs used to treat gliomas (<xref ref-type="bibr" rid="bib30">Lucena-Cacace et al., 2019</xref>; <xref ref-type="bibr" rid="bib29">Lucena-Cacace et al., 2017</xref>) has been suggested, whilst we additionally and concordantly identify <italic>EGFR</italic> amplification as a biomarker (<xref ref-type="fig" rid="fig4">Figure 4F</xref>).</p><p>Another novel and concordant identified biomarker is doramapimod response (also known as BIRB-796) in <italic>ARID2</italic> mutant melanoma cell lines (<xref ref-type="fig" rid="fig4">Figure 4G</xref>). Doramapimod is a small-molecule p38 MAPK inhibitor and has been reported in different cancer types (in combination with other drugs) including cervical cancer, paracrine tumours and myeloma (<xref ref-type="bibr" rid="bib24">Jin et al., 2016</xref>; <xref ref-type="bibr" rid="bib53">Yasui et al., 2007</xref>). ARID2 is part of chromatin remodelling complex and is involved in DNA repair in hepatocellular carcinoma cells (<xref ref-type="bibr" rid="bib35">Oba et al., 2017</xref>) and enriched in melanomas (<xref ref-type="bibr" rid="bib11">Ding et al., 2014</xref>; <xref ref-type="bibr" rid="bib21">Hodis et al., 2012</xref>). In conclusion, different curve fitting approaches lead to concordantly and novel identified biomarkers, thereby increasing the robustness in those findings, and consequently enabling to prioritise hypotheses.</p></sec><sec id="s2-4"><title>Improved biomarker detection by taking into account uncertainty in a Bayesian framework</title><p>Since both Bayesian and frequentist methods can be used to prioritise biomarkers for further testing, we compared association statistics (posterior probabilities and q-values) from both statistical methods. We observed a number of cases where the Bayesian and ANOVA tests disagree (<xref ref-type="fig" rid="fig5">Figure 5A</xref>; <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). For instance, <italic>BRAF</italic> mutations in colorectal cancer were detected as a sensitivity biomarker for dabrafenib by the Bayesian test, but less significant by the ANOVA test. This association had been repeatedly reported in in vitro models (<xref ref-type="bibr" rid="bib23">Iorio et al., 2016</xref>; <xref ref-type="bibr" rid="bib38">Rees et al., 2016</xref>) and also found in melanoma cases (<xref ref-type="bibr" rid="bib4">Chapman et al., 2011</xref>), whilst not in colorectal cancer patients due to feedback activation of ERK-signalling mediated via <italic>EGFR</italic> (<xref ref-type="bibr" rid="bib7">Corcoran et al., 2018</xref>; <xref ref-type="bibr" rid="bib36">Prahallad et al., 2012</xref>). We note in <xref ref-type="fig" rid="fig5">Figure 5B</xref> that the Bayesian test takes advantage of the additional information that sensitive mutant cell lines have low estimation uncertainty, whilst the small number of resistant mutant cell lines have high estimation uncertainty, causing them to have less influence on the biomarker detection. On the other hand, the ANOVA model detected the <italic>KRAS</italic> copy number alteration as a resistance biomarker for lenalidomide (immunomodulatory drug) partial sensitivity in skin cutaneous melanoma (SKCM), whilst not detected by our Bayesian approach. Whilst on the linear IC<sub>50</sub> scale there is some difference between the small number of mutant cell lines and wildtypes, the Bayesian model considered that the estimated responses of the mutant cell lines had high uncertainty (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). Additionally, a comparison of the uncertainty estimates for the GP and the Sigmoid curve fitting methods revealed that both display concordant results (<xref ref-type="fig" rid="fig5">Figure 5B and C</xref>; <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>); However, the Sigmoid curve fitting method (Materials and methods; <xref ref-type="bibr" rid="bib49">Vis et al., 2016</xref>) underestimates variance of non-responding cell lines rendering the GP approach superior. The dosages within <xref ref-type="fig" rid="fig5">Figure 5B and C</xref> were rescaled to prevent the need for adapting the length-scale hyperparameter to the maximum dosage. IC<sub>50</sub> values were back-transformed to the log10 drug dosage scale to make comparisons with (<xref ref-type="bibr" rid="bib23">Iorio et al., 2016</xref>) (see Materials and methods). Whilst discrepancies between Bayesian and ANOVA tests have to be taken with caution, they may highlight novel biological insights which would be missed when applying only a single model.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Comparison of Bayesian testing and ANOVA using the GP IC<sub>50</sub> estimates.</title><p>(<bold>A</bold>) Scatterplot of biomarker associations with IC<sub>50</sub> drug response. The y-axis shows the negative log10 transformed posterior probability of a sign change in the effect under the Bayesian testing model, whilst the x-axis shows the negative log10 of the q-value from ANOVA testing. The size of the circles is proportional to the number of mutants or copy number variations in the given type of cancer cell line. (<bold>B</bold>) GP estimates for the mean and standard deviation of the log(IC<sub>50</sub>) from colorectal cell lines tested with BRAF inhibitor dabrafenib, which showed significant association with <italic>BRAF</italic> mutation in the Bayesian test. (<bold>C</bold>) Estimated IC<sub>50</sub> and its uncertainty for skin cutaneous melanoma cell lines tested with the immunomodulatory drug lenalidomide, which showed significant association with <italic>KRAS</italic> copy number alteration in the ANOVA test. Black vertical lines show the location of the maximum experimental drug dosage. Dose-response curve of the (<bold>D</bold>) MDST8 colorectal cancer cell lines with <italic>BRAF</italic> mutation treated with dabrafenib. The black dotted line represents the maximum concentration of the drug used to treat the cell lines. The blue area represents the 95% confidence intervals in the dose-response fits. (<bold>E</bold>) Similar to (<bold>D</bold>) but for CHL-1 skin cutaneous melanoma cell lines with <italic>KRAS</italic> copy number alteration treated with lenalidomide.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60352-fig5-v3.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Sigmoid curve fitting uncertainty.</title><p>Estimated log10(IC50) and uncertainties based on a bootstrap sampling method, for (<bold>A</bold>) colorectal cell lines tested with dabrafenib and (<bold>B</bold>) skin cutaneous melanoma cell lines tested with lenalidomide. Black vertical line represents the maximum experimental drug dosage.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60352-fig5-figsupp1-v3.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>An overview of the cell viability values.</title><p>(<bold>A</bold>) The distribution of the cell viability values. (<bold>B</bold>) The distribution of negative cell viability values.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60352-fig5-figsupp2-v3.tif"/></fig></fig-group></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>The GP approach developed in this research has several advantages compared to the traditional approach of fitting sigmoidal drug-response curves. Firstly, these flexible, non-parametric models can be used to fit a wider variety of dose-response curves than the parametric sigmoidal models, for example curves of unexpected shapes may reflect biological signals of off-target effects. Secondly, the GP models provide straightforward uncertainty quantification of any summary statistic that can be calculated on a dose-response curve, a fact that we take advantage of in developing our hierarchical Bayesian model for biomarker testing. Thirdly, the GP model can deal with outlying measurements better than a sigmoidal model, due to formulating it as a mixture model with one component representing the latent GP process of the drug response, and the second component accounting for outliers.</p><p>In contrast to other GP-based models in <xref ref-type="bibr" rid="bib45">Tansey et al., 2018</xref>, our approach is highly interpretable, as we do not integrate the biomarkers into the model estimation in a non-linear fashion, but instead proceed in a two-step approach that first fits our Gaussian process model to the dose-response curves, and then uses the derived summary statistics and uncertainty measures to perform biomarker detection. Thus, we can take advantage of the flexibility of the Gaussian process without the complexity of fitting a non-linear neural network to enable prediction from molecular measurements.</p><p>The increased flexibility of the GP model comes at a price. Most notably, because we do not impose a specific functional form, there are few constraints on the behaviour of the curve outside the range of observed dosages. This leads to the counter-intuitive behaviour that the posterior mean estimate of drug response can go up when extrapolating beyond the maximum dosage. Note, however, that this goes along with a commensurate increase in the posterior variance (<xref ref-type="fig" rid="fig5">Figure 5D,E</xref>). In other words, the model is highlighting that extrapolation beyond the observed dosage range is highly uncertain, and the posterior mean estimate should not be relied on. It would be possible to constrain this behaviour by introducing artificial data points at a high concentration, or less crudely by imposing monotonicity constraints via virtual derivative observations (<xref ref-type="bibr" rid="bib39">Riihimäki and Vehtari, 2010</xref>). However, these methods would limit the flexibility of our method and lead us to underestimate the uncertainty of the posterior mean. An alternative approach is to constrain the Gaussian process using generalised analytic slice sampling (<xref ref-type="bibr" rid="bib46">Tansey et al., 2019</xref>), which integrates the constraints into the sampling process. Whilst theoretically appealing, this approach is not compatible with the variational inference method that we have chosen for our work, and would lead to an unacceptable increase in computational burden for fitting the dose-response curves.</p><p>We have systematically compared the application of GP to sigmoid models across a pan-cancer drug screen. We demonstrated that our GP estimates of the IC<sub>50</sub> values and their subsequently predicted biomarkers using ANOVA are reliable when compared to estimates from the sigmoid models. In addition, the GP models provide useful information about the uncertainty associated with the drug-response quantification. However, there is a crucial difference between estimation uncertainty on a single experiment and observational uncertainty across multiple replicates of the same experiment, which incorporates measurement error, technical and biological variation. We are interested in the former to assess the quality of the fit, and therefore the reliability of the estimated IC<sub>50</sub>. We hypothesized that estimation uncertainty characterises observational uncertainty within the dose concentration range tested. However, extrapolating beyond the concentration range would be challenging due to the uncertainty in the behaviour of the dose-response curve in unobserved concentrations. Imposing monotonicity may not be the best path in this case, but we avoid making this assumption. Instead, our method defines a very large confidence interval for drug-response statistics extrapolated beyond the maximum dose tested and we would additionally need to take the observation uncertainty between replicate experiments into account. We have verified this by applying our estimation method to a replication data set of 26 drugs tested on 10 different cell lines, with 8 to 9 replicates for each drug-cell line experiment. We conclude that whilst estimation uncertainty is a useful indicator for within-concentration IC<sub>50</sub> values, it cannot be used as a proxy for observation uncertainty when the IC<sub>50</sub> is extrapolated beyond the tested concentration range. Indeed, overall drug responses and biomarkers from independent drug screens were consistent when comparing similar dose ranges (<xref ref-type="bibr" rid="bib18">Haverty et al., 2016</xref>). Any difference between replicate experiments may be due to batch effects or other unobserved factors that are not necessarily reflected in the estimation error. Whilst previous studies have attempted to capture uncertainty by measuring the spread of the residuals from the fitted curves, such as root mean square error, they were not able to capture these false positive biomarkers by setting strict cutoffs (<xref ref-type="bibr" rid="bib5">Cokelaer et al., 2018</xref>).</p><p>Whilst Bayesian posterior probabilities and ANOVA q-values are different statistical quantities for measuring biomarker associations that should not be compared in absolute terms, we compared these quantities in relative terms to prioritise biomarkers of response for further testing. Our Bayesian biomarker model extends the classical ANOVA testing, since it is able to leverage the estimation uncertainty of the IC<sub>50</sub> values. We showed that taking estimation uncertainty into account in the Bayesian model can lead to both inclusion and exclusion of putative biomarkers. For example, the Bayesian model highlighted the association between <italic>BRAF</italic> mutation in colorectal cancer and BRAF inhibitor response. Targeting BRAF signalling has recently been confirmed as a viable option for metastatic colorectal cancer cases with <italic>BRAF</italic> mutations (<xref ref-type="bibr" rid="bib27">Kopetz et al., 2019</xref>). In contrast, the Bayesian model excluded a suggestion from ANOVA of association between <italic>KRAS</italic> mutation with lenalidomide response in melanoma. Lenalidomide has thus far had no clinical success in <italic>KRAS</italic> mutant cases nor melanoma (<xref ref-type="bibr" rid="bib13">Gandhi et al., 2013</xref>; <xref ref-type="bibr" rid="bib16">Glaspy et al., 2009</xref>).</p><p>Although we systematically tested for drug-biomarker associations, we did observe common behaviour for certain cell types or classes of drugs. The high uncertainty in the response estimates of chromatin histone methylation targeting compounds for instance may be due to the large number of factors contributing to epigenetic regulation of cells (<xref ref-type="bibr" rid="bib31">Luo, 2015</xref>). It would be straightforward to extend the GP model to allow for sharing information across drugs or cell lines of similar class, by using either shared hyperparameters or a hyperprior on the hyperparameters. We have not implemented this approach in our work here as our aim was to show the advantage of fitting individual drug-response using GPs, and extending the method to fitting multiple curves jointly would increase the memory and computational requirements significantly. It is our hope to continue expanding the suite to multiple dimensions of dose-response and biomarker prediction needed for drug combinations, which is predominantly based on synergy modelling with either Loewe Additivity or Bliss Independence (<xref ref-type="bibr" rid="bib10">Di Veroli et al., 2016</xref>; <xref ref-type="bibr" rid="bib50">Vlot et al., 2019</xref>). In cases where multiple statistical models converge to concordant biomarkers, this increases the reproducibility of the evidence, potential for clinical translatability and ultimately enables precision medicine.</p><p>The increasing utilisation of high-throughput drug screening for identifying effective new treatments will necessitate the use of more powerful statistical and machine learning methods (<xref ref-type="bibr" rid="bib48">Toh et al., 2019</xref>). We have introduced an approach for quantifying the uncertainties of dose-response using Gaussian Processes and further described how these uncertainties can be integrated into statistical testing of biomarkers. For cancer treatments, our approach can help estimate the uncertainty of dose-responses reported in the numerous drug screening studies by academic (<xref ref-type="bibr" rid="bib15">Ghandi et al., 2019</xref>; <xref ref-type="bibr" rid="bib22">Holbeck et al., 2017</xref>; <xref ref-type="bibr" rid="bib23">Iorio et al., 2016</xref>) and pharmaceutical laboratories (<xref ref-type="bibr" rid="bib33">Menden et al., 2019</xref>; <xref ref-type="bibr" rid="bib34">O'Neil et al., 2016</xref>). This can provide more robust metrics for comparing drug responses to identify the most potent ones and highlight sensitivity biomarkers that are more likely to succeed clinically because they are associated with low uncertainty. The approach is also generalisable beyond cancer to any disease and any dose-response measures. We hope that by considering response uncertainty and providing a probabilistic view of drug biomarkers, the risks associated with drug development can be better balanced and smarter decisions can be made.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th valign="top">Reagent type <break/>(species) or resource</th><th valign="top">Designation</th><th valign="top">Source or reference</th><th valign="top">Identifiers</th><th valign="top">Additional information</th></tr></thead><tbody><tr><td valign="top">Cell line (<italic>Home sapines</italic>)</td><td valign="top">1074 cancer cell lines</td><td valign="top">(<xref ref-type="bibr" rid="bib23">Iorio et al., 2016</xref>) PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/27397505">27397505</ext-link></td><td valign="top">GDSC cell line drug response:GDSC1 (v17); GDSC cell line genomics:GDSCtools_mobems</td><td valign="top">Further information about the cancer cell lines from the GDSC can be found here: <ext-link ext-link-type="uri" xlink:href="https://www.cancerrxgene.org/">https://www.cancerrxgene.org/</ext-link>downloads/bulk_download</td></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Source code for curve fitting and Bayesian biomarker detection</td><td valign="top">This paper</td><td valign="top"/><td valign="top">All source code can be found via GitHub here: <ext-link ext-link-type="uri" xlink:href="https://github.com/FrankD/GPDrugModels">https://github.com/FrankD/GPDrugModels</ext-link></td></tr><tr><td valign="top">Software, algorithm</td><td valign="top">GPFlow</td><td valign="top">GPFlow (<ext-link ext-link-type="uri" xlink:href="https://www.gpflow.org">https://www.gpflow.org</ext-link>)</td><td valign="top"/><td valign="top">Version 1.5.1</td></tr><tr><td valign="top">Software, algorithm</td><td valign="top">TensorFlow</td><td valign="top">TensorFlow (<ext-link ext-link-type="uri" xlink:href="https://www.tensorflow.org/">https://www.tensorflow.org/</ext-link>)</td><td valign="top"/><td valign="top">Version 1.14.0</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Drug screening</title><p>We analysed 1074 cancer cell lines tested with 265 compounds from a high-throughput screen resulting in 225,384 experiments that were previously published (<xref ref-type="bibr" rid="bib23">Iorio et al., 2016</xref>). Cell line data was retrieved and is publically available via the GDSC website (Key Resources Table). All cell lines were authenticated. Details for each cell line can be found at: <ext-link ext-link-type="uri" xlink:href="https://www.cancerrxgene.org/help">https://www.cancerrxgene.org/help</ext-link>.</p><p>Compounds were tested with 5 to 9 titration points, whilst either diluted with 4- or 2-fold, respectively. Cells were seeded on day zero, left in the microtiter plate for 24 hr to retain linear growth, and consecutively treated for 3 days. After those 3 days of treatment, cellTiterGlo staining is used to quantify ATP levels within each well. In parallel, untreated cells and blank wells were also measured to estimate and normalise cell viability.</p><p>Compounds within the replicate study were screened across a seven point dose-response curve with a half-log dilution and 1000 fold range. The duration of drug treatment was 72 hr and cell viability was measured using CellTiter-Glo (Promega). Each cell line and compound pair was screened in technical triplicate, three assay plates generated simultaneously, and across three biological replicates with 46 and 44 days between the first to second and second to third replicates respectively. Cell viability measurements for these experiments can be found in <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>.</p></sec><sec id="s4-2"><title>Preprocessing</title><p>Prior to analysis, we scaled the raw observed fluorescent intensities for each drug/cell line combination using the observations from the blank and negative control wells as follows. Let <inline-formula><mml:math id="inf1"><mml:mrow><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo> <mml:mrow><mml:msub><mml:mi>r</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>r</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mn>...</mml:mn><mml:mo>,</mml:mo><mml:msub><mml:mi>r</mml:mi><mml:mi>n</mml:mi></mml:msub></mml:mrow> <mml:mo>}</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> be the observed intensities for <italic>n</italic> dosages. Let <italic>B</italic> be the mean of the intensities for the blank wells on the same plate as the experiment, and C be the mean of the intensities of the negative control wells (no drug added). Then the relative cell viability <inline-formula><mml:math id="inf2"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>V</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> can be calculated as:<disp-formula id="equ1"><mml:math id="m1"><mml:mrow><mml:mi>V</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>R</mml:mi><mml:mo> </mml:mo><mml:mo>−</mml:mo><mml:mo> </mml:mo><mml:mi>B</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi><mml:mo> </mml:mo><mml:mo>−</mml:mo><mml:mo> </mml:mo><mml:mi>B</mml:mi><mml:mo> </mml:mo></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula></p><p>Relative cell viability values below 0 (n = 2646, <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>) were set to 0.</p><p>For the purpose of fitting the Gaussian process models, we additionally rescale the dosages to avoid having to adapt the length-scale hyperparameter to the maximum dosage. We rescale the log<sub>2</sub>-transformed dosages <inline-formula><mml:math id="inf3"><mml:mrow><mml:mi>d</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo> <mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mn>...</mml:mn><mml:mo>,</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mi>n</mml:mi></mml:msub></mml:mrow> <mml:mo>}</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> as follows:<disp-formula id="equ2"><mml:math id="m2"><mml:mrow><mml:mi>d</mml:mi><mml:mo>'</mml:mo><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mo> </mml:mo><mml:mo>+</mml:mo><mml:mo> </mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>d</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo> </mml:mo><mml:mo>+</mml:mo><mml:mo> </mml:mo><mml:mn>1</mml:mn><mml:mo> </mml:mo></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula></p><p>Note that IC<sub>50</sub> values have been back-transformed to the log10 drug dosage scale for comparability with those reported in <xref ref-type="bibr" rid="bib23">Iorio et al., 2016</xref>.</p></sec><sec id="s4-3"><title>Sigmoid drug-response model</title><p>The GDSC estimates in <xref ref-type="bibr" rid="bib23">Iorio et al., 2016</xref> were obtained using a sigmoid fit to the drug-response curve, using the same pre-processing of the fluorescent intensities as described above. The particular sigmoid model used is the one described in <xref ref-type="bibr" rid="bib49">Vis et al., 2016</xref>. In brief, if we have shape parameter <inline-formula><mml:math id="inf4"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>s</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> and position parameter <inline-formula><mml:math id="inf5"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> for cell line <inline-formula><mml:math id="inf6"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> and drug <inline-formula><mml:math id="inf7"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> , then cell viability can be represented as a function of dosage <inline-formula><mml:math id="inf8"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>:<disp-formula id="equ3"><mml:math id="m3"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>f</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>d</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>e</mml:mi><mml:mi>x</mml:mi><mml:mi>p</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:math></disp-formula></p><p>Note that this allows for cell line/drug specific position parameters, but shape parameters that only vary by cell line and are shared across drugs. The position parameter <inline-formula><mml:math id="inf9"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> corresponds to the estimated IC<sub>50</sub> for cell line <inline-formula><mml:math id="inf10"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> and drug <inline-formula><mml:math id="inf11"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>. For full details, see <xref ref-type="bibr" rid="bib49">Vis et al., 2016</xref>.</p><p>To estimate the uncertainty of the Sigmoid curve fitting, a random bootstrap sampling of 80% of all treated cell lines available for each drug over 100 iterations was performed. The Sigmoid curve fitting model from GDSC (Vis et al. 2013) estimates one scale parameter per drug across all treated cell lines, thus the sampling creates variance in the response data. The standard deviation of the log(IC<sub>50</sub>) estimates was computed to assess the model’s variance.</p></sec><sec id="s4-4"><title>Gaussian process drug-response model</title><p>For simplicity, we drop the subscripts <inline-formula><mml:math id="inf12"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> and present the combination. We model the drug response <inline-formula><mml:math id="inf13"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mi mathvariant="bold">y</mml:mi></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula> via a two-component Beta mixture such that:<disp-formula id="equ4"><mml:math id="m4"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>P</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi mathvariant="bold">y</mml:mi></mml:mrow><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="bold">f</mml:mi></mml:mrow><mml:mo>,</mml:mo><mml:msub><mml:mi>s</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:msub><mml:mi>μ</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:msub><mml:mi>s</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:mi>π</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mi>π</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>B</mml:mi><mml:mi>e</mml:mi><mml:mi>t</mml:mi><mml:msup><mml:mi>a</mml:mi><mml:mrow><mml:mi>μ</mml:mi></mml:mrow></mml:msup><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi mathvariant="bold">y</mml:mi></mml:mrow><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:msup><mml:mi mathvariant="normal">Φ</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi mathvariant="bold">f</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:msub><mml:mi>s</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>π</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mi>B</mml:mi><mml:mi>e</mml:mi><mml:mi>t</mml:mi><mml:msup><mml:mi>a</mml:mi><mml:mrow><mml:mi>μ</mml:mi></mml:mrow></mml:msup><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi mathvariant="bold">y</mml:mi></mml:mrow><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:msub><mml:mi>μ</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:msub><mml:mi>s</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></disp-formula>where <inline-formula><mml:math id="inf14"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>B</mml:mi><mml:mi>e</mml:mi><mml:mi>t</mml:mi><mml:msup><mml:mi>a</mml:mi><mml:mrow><mml:mi>μ</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mstyle></mml:math></inline-formula> is the reparameterization of the Beta distribution in terms of the mean µ and a scale parameter <inline-formula><mml:math id="inf15"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>, and <inline-formula><mml:math id="inf16"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msup><mml:mi mathvariant="normal">Φ</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mstyle></mml:math></inline-formula> is the probit function (the inverse of the standard normal cumulative distribution function). Component one represents the drug response, which is driven by a latent Gaussian process <inline-formula><mml:math id="inf17"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mi mathvariant="bold">f</mml:mi></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula>, whilst component two represents outliers that deviate from the overall dose- response trend. We set the scale parameters <inline-formula><mml:math id="inf18"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>50</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf19"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>11</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> and specify <inline-formula><mml:math id="inf20"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>μ</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0.9</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> to reflect our belief that outliers will mostly be erroneous measurements of resistance. We set <inline-formula><mml:math id="inf21"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>π</mml:mi><mml:mo>=</mml:mo><mml:mn>0.999</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> as we believe that outliers are rare.</p><p>We place a standard Gaussian process prior on <inline-formula><mml:math id="inf22"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mi mathvariant="bold">f</mml:mi></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula>, such that:<disp-formula id="equ5"><mml:math id="m5"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>P</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi mathvariant="bold">f</mml:mi></mml:mrow><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mi>d</mml:mi><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">Ψ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mi>M</mml:mi><mml:mi>V</mml:mi><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi mathvariant="bold">f</mml:mi><mml:mrow><mml:mo mathvariant="bold" stretchy="false">|</mml:mo></mml:mrow><mml:mi mathvariant="bold">m</mml:mi></mml:mrow><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi mathvariant="normal">Ψ</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>d</mml:mi><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:msup><mml:mi>d</mml:mi><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></disp-formula>where <inline-formula><mml:math id="inf23"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mi mathvariant="bold">m</mml:mi></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula> is the mean drug response, and <inline-formula><mml:math id="inf24"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi mathvariant="normal">Ψ</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>d</mml:mi><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:msup><mml:mi>d</mml:mi><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula> is a covariance function with hyperparameters <inline-formula><mml:math id="inf25"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Ψ</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>; in practice we choose a combined linear-Matern3/2 as a flexible option, which avoids the excessive smoothness of restrictions of the commonly used RBF kernel. Stein (1999) argues that this is a more realistic representation for physical processes (<xref ref-type="bibr" rid="bib43">Stein, 2012</xref>). Information sharing across drugs and cell lines can be achieved via shared hyperpriors in a hierarchical model. For the application in this paper joint inference with shared hyperpriors would be computationally difficult, and we choose to instead empirically set the variance and length-scale parameters for the Matern to 0.2 and 0.3, respectively, and the variance parameter for the linear kernel to 0.1.</p><p>Inference is performed using variational learning (<xref ref-type="bibr" rid="bib19">Hensman et al., 2013</xref>), via the GPFlow software (<xref ref-type="bibr" rid="bib32">Matthews AG de and van der Wilk, 2017</xref>). We choose variational learning over alternatives such as Markov chain Monte Carlo due to its speed, which allows us to process large drug-response panels in a realistic time frame. Hyperparameters for the GP model were determined by manual tuning; however, for other datasets, we could also envision a Bayesian model selection procedure which places the variational inference in a variational-within-MCMC scheme where the MCMC moves update the hyperparameters. If fixed hyperparameters are desired, one could use the maximum a posteriori values. To avoid massive computational complexity, the MCMC scheme could be run on a representative subsample of cell lines.</p></sec><sec id="s4-5"><title>Calculation of summary statistics</title><p>Summary statistics of drug response can be calculated straightforwardly by sampling from the posterior of the Gaussian process (<xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>). Generally, let <inline-formula><mml:math id="inf26"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>g</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi mathvariant="bold">d</mml:mi><mml:mo mathvariant="bold">,</mml:mo><mml:mspace width="thinmathspace"/><mml:mi mathvariant="bold">y</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula> be a function that calculates a summary statistic <inline-formula><mml:math id="inf27"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>τ</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> from a dose-response curve with dosages <inline-formula><mml:math id="inf28"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mi mathvariant="bold">d</mml:mi></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula> and responses <inline-formula><mml:math id="inf29"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mi mathvariant="bold">y</mml:mi></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula>, then we can obtain a posterior estimate of the mean of the summary statistic by first sampling <inline-formula><mml:math id="inf30"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>N</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> dose-response curves from the posterior of the GP model, and then calculating the average:<disp-formula id="equ6"><mml:math id="m6"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mover><mml:mi>τ</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>N</mml:mi></mml:mfrac><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>l</mml:mi></mml:mrow><mml:mrow><mml:mi>N</mml:mi></mml:mrow></mml:munderover><mml:mrow><mml:mi>g</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="bold">d</mml:mi></mml:mrow><mml:mi>l</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:msub><mml:mrow><mml:mi mathvariant="bold">y</mml:mi></mml:mrow><mml:mi>l</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></disp-formula></p><p>A similar procedure can be used to calculate the posterior estimate of the standard deviation.</p><p>Although we can extract other response statistics from our curve fits, the most common are the IC<sub>50</sub> and the area under the drug-response curve (AUC). On the log<sub>2</sub> dosage scale the dosages are equally spaced, and hence AUC can be straightforwardly estimated by the mean function:<disp-formula id="equ7"><mml:math id="m7"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>g</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi mathvariant="bold">d</mml:mi><mml:mo mathvariant="bold">,</mml:mo><mml:mspace width="thinmathspace"/><mml:mrow><mml:mi mathvariant="bold">y</mml:mi></mml:mrow></mml:mrow><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>n</mml:mi></mml:mfrac><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:munderover><mml:mrow><mml:msub><mml:mi>y</mml:mi><mml:mi>m</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:mstyle></mml:math></disp-formula>where <inline-formula><mml:math id="inf31"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> indexes over the <inline-formula><mml:math id="inf32"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> dosages. For the IC<sub>50</sub>, estimation for a single curve is complicated by the fact that the curve may not cross the 50% viability threshold within the observed dosage range (non-crossing sample). We therefore extrapolate the GP samples to 10 times the maximum (log<sub>2</sub>) experimental dosage and specify <inline-formula><mml:math id="inf33"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>g</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi mathvariant="bold">d</mml:mi><mml:mo mathvariant="bold">,</mml:mo><mml:mspace width="thinmathspace"/><mml:mrow><mml:mi mathvariant="bold">y</mml:mi></mml:mrow></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula> as:<disp-formula id="equ8"><mml:math id="m8"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>g</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi mathvariant="bold">d</mml:mi><mml:mo mathvariant="bold">,</mml:mo><mml:mspace width="thinmathspace"/><mml:mi mathvariant="bold">y</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mi>m</mml:mi></mml:msub><mml:mspace width="thinmathspace"/><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">h</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">h</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow><mml:mspace width="thinmathspace"/><mml:msub><mml:mi mathvariant="normal">y</mml:mi><mml:mi mathvariant="normal">m</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>0.5</mml:mn><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">∃</mml:mi><mml:msub><mml:mi mathvariant="normal">y</mml:mi><mml:mi mathvariant="normal">m</mml:mi></mml:msub><mml:mo>≤</mml:mo><mml:mn>0.5</mml:mn></mml:mrow></mml:mstyle></mml:math></disp-formula></p><p>Note that this ignores samples where for all dosages, <inline-formula><mml:math id="inf34"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>y</mml:mi><mml:mi>m</mml:mi></mml:msub><mml:mo>≤</mml:mo><mml:mn>0.5</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>; one could devise a multivariate sufficient statistic that takes this information into account, but we have found that in general there is a reasonable amount of correlation between <inline-formula><mml:math id="inf35"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>g</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi mathvariant="bold">d</mml:mi><mml:mo mathvariant="bold">,</mml:mo><mml:mspace width="thinmathspace"/><mml:mi mathvariant="bold">y</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula> and the number of non-crossing samples for a given cell line/drug combination.</p></sec><sec id="s4-6"><title>Comparison of GP and sigmoid IC<sub>50</sub> values</title><p>Concordance between IC<sub>50</sub> values based on sigmoid and GP-curve fitting is quantified with Pearson correlation for each drug. To account for tissue specificity and the varying number of cell lines assessed per tissue type, we employed the average weighted Pearson correlation (<inline-formula><mml:math id="inf36"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>p</mml:mi><mml:mi>w</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>) of the sigmoid-curve versus GP-curve fitted IC<sub>50</sub> values for the individual cancer types (<inline-formula><mml:math id="inf37"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>).</p><p>The weight for a given cancer type <inline-formula><mml:math id="inf38"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> was denoted as <inline-formula><mml:math id="inf39"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msqrt><mml:msub><mml:mi>n</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:msqrt></mml:mrow></mml:mstyle></mml:math></inline-formula>, where <inline-formula><mml:math id="inf40"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> is the total number of cell lines treated with the drug within this tissue type. The following metric was applied,<disp-formula id="equ9"><mml:math id="m9"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>p</mml:mi><mml:mi>w</mml:mi><mml:mo>=</mml:mo><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>h</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mfrac><mml:mrow><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>N</mml:mi></mml:mrow></mml:munderover><mml:mrow><mml:msqrt><mml:msub><mml:mi>n</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:msqrt><mml:mspace width="thinmathspace"/><mml:mi>a</mml:mi><mml:mi>r</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>h</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>N</mml:mi></mml:mrow></mml:munderover><mml:mrow><mml:msqrt><mml:msub><mml:mi>n</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:msqrt></mml:mrow></mml:mrow></mml:mfrac><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></disp-formula>where <inline-formula><mml:math id="inf41"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> is unweighted Pearson correlation within a cancer type (<inline-formula><mml:math id="inf42"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>) and a total number of tested cancer types is <inline-formula><mml:math id="inf43"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>N</mml:mi><mml:mo>=</mml:mo><mml:mn>30</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>. For a given drug and tissue type combination, at least 10 cell lines need to be treated (<inline-formula><mml:math id="inf44"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>≥</mml:mo><mml:mn>10</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>).</p><p>Differences in IC<sub>50</sub> values for each drug-response value <italic>j</italic> were consistently defined as<disp-formula id="equ10"><mml:math id="m10"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>f</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:msub><mml:mn>50</mml:mn><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>G</mml:mi><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:msub><mml:mn>50</mml:mn><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>g</mml:mi><mml:mi>m</mml:mi><mml:mi>o</mml:mi><mml:mi>i</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></disp-formula>with a total number of tested cell line and drug combinations equalling to <inline-formula><mml:math id="inf45"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>171</mml:mn><mml:mo>,</mml:mo><mml:mn>937</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>.</p></sec><sec id="s4-7"><title>Bayesian biomarker testing</title><p>Standard statistical approaches for testing the influence of biomarkers on drug response mostly rely on analysis of variance (ANOVA) testing. An ANOVA can be understood as a linear model of the dependent variable <inline-formula><mml:math id="inf46"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> (in this case, a summary measure of drug response such as IC<sub>50</sub>):<disp-formula id="equ11"><mml:math id="m11"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>g</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mi>α</mml:mi><mml:mo>+</mml:mo><mml:mi>β</mml:mi><mml:msub><mml:mi>z</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mi>γ</mml:mi><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>ϵ</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mstyle></mml:math></disp-formula>where <inline-formula><mml:math id="inf47"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> is an indicator variable denoting the group membership of data point <inline-formula><mml:math id="inf48"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>. In our application, the data points are cell lines, <inline-formula><mml:math id="inf49"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>z</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> indicates group membership, for example the mutation status of a given SNP, and <inline-formula><mml:math id="inf50"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> indicates any other covariates that we wish to correct for, such as tissue type. The parameter <inline-formula><mml:math id="inf51"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>α</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> captures the global mean of the drug response, whilst <inline-formula><mml:math id="inf52"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>β</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> captures the effect of mutation status on the drug response, <inline-formula><mml:math id="inf53"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>γ</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> is the effect of covariates, and <inline-formula><mml:math id="inf54"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>ϵ</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> is independent Gaussian noise.</p><p>This model, whilst useful, fails to account for the fact that our Gaussian process model provides estimates <inline-formula><mml:math id="inf55"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>σ</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> of the uncertainty (or standard error) associated with the mean IC<sub>50</sub> estimates <inline-formula><mml:math id="inf56"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>g</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>. In order to make use of these uncertainty estimates, we take an idea from Bayesian meta-analysis, and integrate them via a hierarchical model:<disp-formula id="equ12"><mml:math id="m12"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mtable columnalign="center center" columnspacing="1em" rowspacing="4pt"><mml:mtr><mml:mtd><mml:msub><mml:mi>g</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>∼</mml:mo><mml:mrow><mml:mi mathvariant="script">𝒩</mml:mi></mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>i</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msub><mml:mi>μ</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>∼</mml:mo><mml:mrow><mml:mi mathvariant="script">𝒩</mml:mi></mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>α</mml:mi><mml:mo>+</mml:mo><mml:mi>β</mml:mi><mml:msub><mml:mi>z</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>γ</mml:mi><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:msup><mml:mi>σ</mml:mi><mml:mrow><mml:mo>∗</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mstyle></mml:math></disp-formula>where <inline-formula><mml:math id="inf57"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>μ</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> is the mean drug-response estimate for cell line <inline-formula><mml:math id="inf58"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>, and <inline-formula><mml:math id="inf59"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msup><mml:mi>σ</mml:mi><mml:mrow><mml:mo>∗</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mstyle></mml:math></inline-formula> is the variance across cell lines (the variance of <inline-formula><mml:math id="inf60"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>ϵ</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> in the ANOVA example). Note that this model can be reduced to:<disp-formula id="equ13"><mml:math id="m13"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>g</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>∼</mml:mo><mml:mrow><mml:mi mathvariant="script">𝒩</mml:mi></mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>α</mml:mi><mml:mo>+</mml:mo><mml:mi>β</mml:mi><mml:msub><mml:mi>z</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>γ</mml:mi><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:msubsup><mml:mi>σ</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msup><mml:mi>σ</mml:mi><mml:mrow><mml:mo>∗</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></disp-formula></p><p>We further specify a Gaussian prior <inline-formula><mml:math id="inf61"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>β</mml:mi><mml:mo>∼</mml:mo><mml:mrow><mml:mi mathvariant="script">𝒩</mml:mi></mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:mn>0.1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula> on the effect size parameter to discourage false positives and reflect our prior belief that most mutations are not associated with drug response. We also place an exponential prior <inline-formula><mml:math id="inf62"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msup><mml:mi>σ</mml:mi><mml:mrow><mml:mo>∗</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>∼</mml:mo><mml:mi>E</mml:mi><mml:mi>x</mml:mi><mml:mi>p</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>10</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula> to regularize the variance parameter. Finally, <inline-formula><mml:math id="inf63"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>α</mml:mi><mml:mo>∼</mml:mo><mml:mrow><mml:mi mathvariant="script">𝒩</mml:mi></mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msup><mml:mi>τ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula> is a Gaussian prior on the global mean with standard error <inline-formula><mml:math id="inf64"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>τ</mml:mi><mml:mo>∼</mml:mo><mml:mi>G</mml:mi><mml:mi>a</mml:mi><mml:mi>m</mml:mi><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula>. Early exploratory results showed that using the estimates of <inline-formula><mml:math id="inf65"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>σ</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> directly placed too much weight on experiments with very low estimation uncertainty, leading to unrealistic posterior estimates of the effect size <inline-formula><mml:math id="inf66"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>β</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>. To attenuate this, we used a transformed estimate <inline-formula><mml:math id="inf67"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>i</mml:mi><mml:mi>c</mml:mi></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula>, where the effect of parameter <inline-formula><mml:math id="inf68"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>c</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> was explored over the range [0,1], and empirically set to 0.25 for the results reported in this paper. The main tuneable hyperparameter is the scaling parameter c, as the model is robust to changes to the parameters for the sparse priors on <inline-formula><mml:math id="inf69"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>β</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf70"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msup><mml:mi>σ</mml:mi><mml:mrow><mml:mo>∗</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mstyle></mml:math></inline-formula>. Setting this hyperparameter is straightforward, as we can use a simple line search to find a value that optimally trades off between disregarding the uncertainty estimates (c = 0) and placing too much weights on estimates with low uncertainty (c &gt;= 1). One way to determine the optimal value for c is to randomly permute the biomarker labels, and reduce c until the false positive rate is below some acceptable threshold.</p><p>Inference in this model is performed using Hamiltonian Monte Carlo via the Stan software package <xref ref-type="bibr" rid="bib3">Carpenter, 2017</xref>. We report the posterior mode of <inline-formula><mml:math id="inf71"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>β</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> as well as the posterior probability of observing <inline-formula><mml:math id="inf72"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>β</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> (if the posterior mode is positive) or <inline-formula><mml:math id="inf73"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>β</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> (if the posterior mode is negative).</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>The MJG laboratory is supported by the Wellcome Trust (206194). DW is supported by the NIHR Sheffield Biomedical Research Centre, Rosetrees Trust (ref: A2501), and the Academy of Medical Sciences Springboard (ref: SBF004/1052). MPM is supported by the European Union's Horizon 2020 Research and Innovation Programme (Grant agreement No. 950293 - COMBAT-RES). We thank Benjamin Sidders and Oliver Stegle for feedback on the methodology. We also thank the Sheffield Bioinformatics Core for help with data preprocessing.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>James Hensman is an employee of Amazon.com. The author has no competing financial interests to declare.</p></fn><fn fn-type="COI-statement" id="conf3"><p>Jonathan Dry is affiliated with AstraZeneca and Tempus. The author has no competing financial interests to declare.</p></fn><fn fn-type="COI-statement" id="conf4"><p>Frank Dondelinger is an employee of Roche. The author has no competing financial interests to declare.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Validation, Investigation, Visualization, Methodology, Writing - original draft</p></fn><fn fn-type="con" id="con2"><p>Software, Formal analysis, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis, Validation, Visualization, Writing - original draft</p></fn><fn fn-type="con" id="con4"><p>Data curation, Formal analysis, Visualization, Writing - original draft, Project administration</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Formal analysis, Supervision, Validation, Writing - review and editing</p></fn><fn fn-type="con" id="con6"><p>Resources, Validation, Data Curation</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Supervision, Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con8"><p>Resources, Data curation, Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con9"><p>Resources, Data curation, Formal analysis, Investigation, Visualization, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Investigation, Visualization, Methodology, Writing - original draft, Project administration</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Validation, Visualization, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Summary of pharmacogenomic associations based on ANOVA.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-60352-supp1-v3.xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Pharmacogenomic associations based on Bayesian testing of GP-curve fits.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-60352-supp2-v3.xlsx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>Raw and curve fitted replicate dataset.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-60352-supp3-v3.xlsx"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>GP-curve fits dataset with calculated summary statistics.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-60352-supp4-v3.xlsx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-60352-transrepform-v3.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data is available through the GDSC downloads portal (<ext-link ext-link-type="uri" xlink:href="ftp://ftp.sanger.ac.uk/pub4/cancerrxgene/releases">ftp://ftp.sanger.ac.uk/pub4/cancerrxgene/releases</ext-link>). Raw dose response data have been deposited in GDSC under v17a_public_raw_data.csv (<ext-link ext-link-type="uri" xlink:href="ftp://ftp.sanger.ac.uk/pub4/cancerrxgene/releases/release-6.0/v17a_public_raw_data.csv">ftp://ftp.sanger.ac.uk/pub4/cancerrxgene/releases/release-6.0/v17a_public_raw_data.csv</ext-link>). Sigmoid fitted dose-response curves have been deposited in GDSC under v17_fitted_dose_response.csv (<ext-link ext-link-type="uri" xlink:href="ftp://ftp.sanger.ac.uk/pub4/cancerrxgene/releases/release-6.0/v17_fitted_dose_response.xlsx">ftp://ftp.sanger.ac.uk/pub4/cancerrxgene/releases/release-6.0/v17_fitted_dose_response.xlsx</ext-link>). Cell line genomics data have been deposited in GDSC under GDSCtools_mobems.zip (<ext-link ext-link-type="uri" xlink:href="ftp://ftp.sanger.ac.uk/pub4/cancerrxgene/releases/release-8.0/GDSCtools_mobems.zip">ftp://ftp.sanger.ac.uk/pub4/cancerrxgene/releases/release-8.0/GDSCtools_mobems.zip</ext-link>). Cell line identity details have been deposited in GDSC under Cell_Lines_Details.xlsx (<ext-link ext-link-type="uri" xlink:href="ftp://ftp.sanger.ac.uk/pub4/cancerrxgene/releases/release-7.0/Cell_Lines_Details.xlsx">ftp://ftp.sanger.ac.uk/pub4/cancerrxgene/releases/release-7.0/Cell_Lines_Details.xlsx</ext-link>). Drug compound details have been deposited in GDSC under screened_compunds_rel_8.2.csv (<ext-link ext-link-type="uri" xlink:href="ftp://ftp.sanger.ac.uk/pub4/cancerrxgene/releases/release-6.0/Screened_Compounds.xlsx">ftp://ftp.sanger.ac.uk/pub4/cancerrxgene/releases/release-6.0/Screened_Compounds.xlsx</ext-link>).</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arrowsmith</surname> <given-names>J</given-names></name><name><surname>Miller</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Phase II and phase III attrition rates 2011–2012</article-title><source>Nature Reviews Drug Discovery</source><volume>12</volume><elocation-id>569</elocation-id><pub-id pub-id-type="doi">10.1038/nrd4090</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boukouvalas</surname> <given-names>A</given-names></name><name><surname>Hensman</surname> <given-names>J</given-names></name><name><surname>Rattray</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>BGP: identifying gene-specific branching dynamics from single-cell data with a branching gaussian process</article-title><source>Genome Biology</source><volume>19</volume><elocation-id>65</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-018-1440-2</pub-id><pub-id pub-id-type="pmid">29843817</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carpenter</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Stan: a probabilistic programming language</article-title><source>Journal of Statistical Software</source><volume>76</volume><elocation-id>i01</elocation-id><pub-id pub-id-type="doi">10.18637/jss.v076.i01</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chapman</surname> <given-names>PB</given-names></name><name><surname>Hauschild</surname> <given-names>A</given-names></name><name><surname>Robert</surname> <given-names>C</given-names></name><name><surname>Haanen</surname> <given-names>JB</given-names></name><name><surname>Ascierto</surname> <given-names>P</given-names></name><name><surname>Larkin</surname> <given-names>J</given-names></name><name><surname>Dummer</surname> <given-names>R</given-names></name><name><surname>Garbe</surname> <given-names>C</given-names></name><name><surname>Testori</surname> <given-names>A</given-names></name><name><surname>Maio</surname> <given-names>M</given-names></name><name><surname>Hogg</surname> <given-names>D</given-names></name><name><surname>Lorigan</surname> <given-names>P</given-names></name><name><surname>Lebbe</surname> <given-names>C</given-names></name><name><surname>Jouary</surname> <given-names>T</given-names></name><name><surname>Schadendorf</surname> <given-names>D</given-names></name><name><surname>Ribas</surname> <given-names>A</given-names></name><name><surname>O'Day</surname> <given-names>SJ</given-names></name><name><surname>Sosman</surname> <given-names>JA</given-names></name><name><surname>Kirkwood</surname> <given-names>JM</given-names></name><name><surname>Eggermont</surname> <given-names>AM</given-names></name><name><surname>Dreno</surname> <given-names>B</given-names></name><name><surname>Nolop</surname> <given-names>K</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Nelson</surname> <given-names>B</given-names></name><name><surname>Hou</surname> <given-names>J</given-names></name><name><surname>Lee</surname> <given-names>RJ</given-names></name><name><surname>Flaherty</surname> <given-names>KT</given-names></name><name><surname>McArthur</surname> <given-names>GA</given-names></name><collab>BRIM-3 Study Group</collab></person-group><year iso-8601-date="2011">2011</year><article-title>Improved survival with vemurafenib in melanoma with BRAF V600E mutation</article-title><source>New England Journal of Medicine</source><volume>364</volume><fpage>2507</fpage><lpage>2516</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1103782</pub-id><pub-id pub-id-type="pmid">21639808</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cokelaer</surname> <given-names>T</given-names></name><name><surname>Chen</surname> <given-names>E</given-names></name><name><surname>Iorio</surname> <given-names>F</given-names></name><name><surname>Menden</surname> <given-names>MP</given-names></name><name><surname>Lightfoot</surname> <given-names>H</given-names></name><name><surname>Saez-Rodriguez</surname> <given-names>J</given-names></name><name><surname>Garnett</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>GDSCTools for mining pharmacogenomic interactions in cancer</article-title><source>Bioinformatics</source><volume>34</volume><fpage>1226</fpage><lpage>1228</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btx744</pub-id><pub-id pub-id-type="pmid">29186349</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cook</surname> <given-names>D</given-names></name><name><surname>Brown</surname> <given-names>D</given-names></name><name><surname>Alexander</surname> <given-names>R</given-names></name><name><surname>March</surname> <given-names>R</given-names></name><name><surname>Morgan</surname> <given-names>P</given-names></name><name><surname>Satterthwaite</surname> <given-names>G</given-names></name><name><surname>Pangalos</surname> <given-names>MN</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework</article-title><source>Nature Reviews Drug Discovery</source><volume>13</volume><fpage>419</fpage><lpage>431</lpage><pub-id pub-id-type="doi">10.1038/nrd4309</pub-id><pub-id pub-id-type="pmid">24833294</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corcoran</surname> <given-names>RB</given-names></name><name><surname>André</surname> <given-names>T</given-names></name><name><surname>Atreya</surname> <given-names>CE</given-names></name><name><surname>Schellens</surname> <given-names>JHM</given-names></name><name><surname>Yoshino</surname> <given-names>T</given-names></name><name><surname>Bendell</surname> <given-names>JC</given-names></name><name><surname>Hollebecque</surname> <given-names>A</given-names></name><name><surname>McRee</surname> <given-names>AJ</given-names></name><name><surname>Siena</surname> <given-names>S</given-names></name><name><surname>Middleton</surname> <given-names>G</given-names></name><name><surname>Muro</surname> <given-names>K</given-names></name><name><surname>Gordon</surname> <given-names>MS</given-names></name><name><surname>Tabernero</surname> <given-names>J</given-names></name><name><surname>Yaeger</surname> <given-names>R</given-names></name><name><surname>O'Dwyer</surname> <given-names>PJ</given-names></name><name><surname>Humblet</surname> <given-names>Y</given-names></name><name><surname>De Vos</surname> <given-names>F</given-names></name><name><surname>Jung</surname> <given-names>AS</given-names></name><name><surname>Brase</surname> <given-names>JC</given-names></name><name><surname>Jaeger</surname> <given-names>S</given-names></name><name><surname>Bettinger</surname> <given-names>S</given-names></name><name><surname>Mookerjee</surname> <given-names>B</given-names></name><name><surname>Rangwala</surname> <given-names>F</given-names></name><name><surname>Van Cutsem</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Combined <italic>BRAF</italic>, EGFR, and MEK inhibition in patients with <italic>BRAF</italic><sup>V600E</sup>-Mutant Colorectal Cancer</article-title><source>Cancer Discovery</source><volume>8</volume><fpage>428</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-17-1226</pub-id><pub-id pub-id-type="pmid">29431699</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costello</surname> <given-names>JC</given-names></name><name><surname>Heiser</surname> <given-names>LM</given-names></name><name><surname>Georgii</surname> <given-names>E</given-names></name><name><surname>Gönen</surname> <given-names>M</given-names></name><name><surname>Menden</surname> <given-names>MP</given-names></name><name><surname>Wang</surname> <given-names>NJ</given-names></name><name><surname>Bansal</surname> <given-names>M</given-names></name><name><surname>Ammad-ud-din</surname> <given-names>M</given-names></name><name><surname>Hintsanen</surname> <given-names>P</given-names></name><name><surname>Khan</surname> <given-names>SA</given-names></name><name><surname>Mpindi</surname> <given-names>JP</given-names></name><name><surname>Kallioniemi</surname> <given-names>O</given-names></name><name><surname>Honkela</surname> <given-names>A</given-names></name><name><surname>Aittokallio</surname> <given-names>T</given-names></name><name><surname>Wennerberg</surname> <given-names>K</given-names></name><name><surname>Collins</surname> <given-names>JJ</given-names></name><name><surname>Gallahan</surname> <given-names>D</given-names></name><name><surname>Singer</surname> <given-names>D</given-names></name><name><surname>Saez-Rodriguez</surname> <given-names>J</given-names></name><name><surname>Kaski</surname> <given-names>S</given-names></name><name><surname>Gray</surname> <given-names>JW</given-names></name><name><surname>Stolovitzky</surname> <given-names>G</given-names></name><collab>NCI DREAM Community</collab></person-group><year iso-8601-date="2014">2014</year><article-title>A community effort to assess and improve drug sensitivity prediction algorithms</article-title><source>Nature Biotechnology</source><volume>32</volume><fpage>1202</fpage><lpage>1212</lpage><pub-id pub-id-type="doi">10.1038/nbt.2877</pub-id><pub-id pub-id-type="pmid">24880487</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dawson</surname> <given-names>DA</given-names></name><name><surname>Genco</surname> <given-names>N</given-names></name><name><surname>Bensinger</surname> <given-names>HM</given-names></name><name><surname>Guinn</surname> <given-names>D</given-names></name><name><surname>Il'giovine</surname> <given-names>ZJ</given-names></name><name><surname>Wayne Schultz</surname> <given-names>T</given-names></name><name><surname>Pöch</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Evaluation of an asymmetry parameter for curve-fitting in single-chemical and mixture toxicity assessment</article-title><source>Toxicology</source><volume>292</volume><fpage>156</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1016/j.tox.2011.12.006</pub-id><pub-id pub-id-type="pmid">22210403</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Veroli</surname> <given-names>GY</given-names></name><name><surname>Fornari</surname> <given-names>C</given-names></name><name><surname>Wang</surname> <given-names>D</given-names></name><name><surname>Mollard</surname> <given-names>S</given-names></name><name><surname>Bramhall</surname> <given-names>JL</given-names></name><name><surname>Richards</surname> <given-names>FM</given-names></name><name><surname>Jodrell</surname> <given-names>DI</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Combenefit: an interactive platform for the analysis and visualization of drug combinations</article-title><source>Bioinformatics</source><volume>32</volume><fpage>2866</fpage><lpage>2868</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btw230</pub-id><pub-id pub-id-type="pmid">27153664</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname> <given-names>L</given-names></name><name><surname>Kim</surname> <given-names>M</given-names></name><name><surname>Kanchi</surname> <given-names>KL</given-names></name><name><surname>Dees</surname> <given-names>ND</given-names></name><name><surname>Lu</surname> <given-names>C</given-names></name><name><surname>Griffith</surname> <given-names>M</given-names></name><name><surname>Fenstermacher</surname> <given-names>D</given-names></name><name><surname>Sung</surname> <given-names>H</given-names></name><name><surname>Miller</surname> <given-names>CA</given-names></name><name><surname>Goetz</surname> <given-names>B</given-names></name><name><surname>Wendl</surname> <given-names>MC</given-names></name><name><surname>Griffith</surname> <given-names>O</given-names></name><name><surname>Cornelius</surname> <given-names>LA</given-names></name><name><surname>Linette</surname> <given-names>GP</given-names></name><name><surname>McMichael</surname> <given-names>JF</given-names></name><name><surname>Sondak</surname> <given-names>VK</given-names></name><name><surname>Fields</surname> <given-names>RC</given-names></name><name><surname>Ley</surname> <given-names>TJ</given-names></name><name><surname>Mulé</surname> <given-names>JJ</given-names></name><name><surname>Wilson</surname> <given-names>RK</given-names></name><name><surname>Weber</surname> <given-names>JS</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Clonal architectures and driver mutations in metastatic melanomas</article-title><source>PLOS ONE</source><volume>9</volume><elocation-id>e111153</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0111153</pub-id><pub-id pub-id-type="pmid">25393105</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fallahi-Sichani</surname> <given-names>M</given-names></name><name><surname>Honarnejad</surname> <given-names>S</given-names></name><name><surname>Heiser</surname> <given-names>LM</given-names></name><name><surname>Gray</surname> <given-names>JW</given-names></name><name><surname>Sorger</surname> <given-names>PK</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Metrics other than potency reveal systematic variation in responses to cancer drugs</article-title><source>Nature Chemical Biology</source><volume>9</volume><fpage>708</fpage><lpage>714</lpage><pub-id pub-id-type="doi">10.1038/nchembio.1337</pub-id><pub-id pub-id-type="pmid">24013279</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gandhi</surname> <given-names>AK</given-names></name><name><surname>Shi</surname> <given-names>T</given-names></name><name><surname>Li</surname> <given-names>M</given-names></name><name><surname>Jungnelius</surname> <given-names>U</given-names></name><name><surname>Romano</surname> <given-names>A</given-names></name><name><surname>Tabernero</surname> <given-names>J</given-names></name><name><surname>Siena</surname> <given-names>S</given-names></name><name><surname>Schafer</surname> <given-names>PH</given-names></name><name><surname>Chopra</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Immunomodulatory effects in a phase II study of lenalidomide combined with cetuximab in refractory KRAS-mutant metastatic colorectal Cancer patients</article-title><source>PLOS ONE</source><volume>8</volume><elocation-id>e80437</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0080437</pub-id><pub-id pub-id-type="pmid">24244687</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garnett</surname> <given-names>MJ</given-names></name><name><surname>Edelman</surname> <given-names>EJ</given-names></name><name><surname>Heidorn</surname> <given-names>SJ</given-names></name><name><surname>Greenman</surname> <given-names>CD</given-names></name><name><surname>Dastur</surname> <given-names>A</given-names></name><name><surname>Lau</surname> <given-names>KW</given-names></name><name><surname>Greninger</surname> <given-names>P</given-names></name><name><surname>Thompson</surname> <given-names>IR</given-names></name><name><surname>Luo</surname> <given-names>X</given-names></name><name><surname>Soares</surname> <given-names>J</given-names></name><name><surname>Liu</surname> <given-names>Q</given-names></name><name><surname>Iorio</surname> <given-names>F</given-names></name><name><surname>Surdez</surname> <given-names>D</given-names></name><name><surname>Chen</surname> <given-names>L</given-names></name><name><surname>Milano</surname> <given-names>RJ</given-names></name><name><surname>Bignell</surname> <given-names>GR</given-names></name><name><surname>Tam</surname> <given-names>AT</given-names></name><name><surname>Davies</surname> <given-names>H</given-names></name><name><surname>Stevenson</surname> <given-names>JA</given-names></name><name><surname>Barthorpe</surname> <given-names>S</given-names></name><name><surname>Lutz</surname> <given-names>SR</given-names></name><name><surname>Kogera</surname> <given-names>F</given-names></name><name><surname>Lawrence</surname> <given-names>K</given-names></name><name><surname>McLaren-Douglas</surname> <given-names>A</given-names></name><name><surname>Mitropoulos</surname> <given-names>X</given-names></name><name><surname>Mironenko</surname> <given-names>T</given-names></name><name><surname>Thi</surname> <given-names>H</given-names></name><name><surname>Richardson</surname> <given-names>L</given-names></name><name><surname>Zhou</surname> <given-names>W</given-names></name><name><surname>Jewitt</surname> <given-names>F</given-names></name><name><surname>Zhang</surname> <given-names>T</given-names></name><name><surname>O'Brien</surname> <given-names>P</given-names></name><name><surname>Boisvert</surname> <given-names>JL</given-names></name><name><surname>Price</surname> <given-names>S</given-names></name><name><surname>Hur</surname> <given-names>W</given-names></name><name><surname>Yang</surname> <given-names>W</given-names></name><name><surname>Deng</surname> <given-names>X</given-names></name><name><surname>Butler</surname> <given-names>A</given-names></name><name><surname>Choi</surname> <given-names>HG</given-names></name><name><surname>Chang</surname> <given-names>JW</given-names></name><name><surname>Baselga</surname> <given-names>J</given-names></name><name><surname>Stamenkovic</surname> <given-names>I</given-names></name><name><surname>Engelman</surname> <given-names>JA</given-names></name><name><surname>Sharma</surname> <given-names>SV</given-names></name><name><surname>Delattre</surname> <given-names>O</given-names></name><name><surname>Saez-Rodriguez</surname> <given-names>J</given-names></name><name><surname>Gray</surname> <given-names>NS</given-names></name><name><surname>Settleman</surname> <given-names>J</given-names></name><name><surname>Futreal</surname> <given-names>PA</given-names></name><name><surname>Haber</surname> <given-names>DA</given-names></name><name><surname>Stratton</surname> <given-names>MR</given-names></name><name><surname>Ramaswamy</surname> <given-names>S</given-names></name><name><surname>McDermott</surname> <given-names>U</given-names></name><name><surname>Benes</surname> <given-names>CH</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Systematic identification of genomic markers of drug sensitivity in cancer cells</article-title><source>Nature</source><volume>483</volume><fpage>570</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1038/nature11005</pub-id><pub-id pub-id-type="pmid">22460902</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghandi</surname> <given-names>M</given-names></name><name><surname>Huang</surname> <given-names>FW</given-names></name><name><surname>Jané-Valbuena</surname> <given-names>J</given-names></name><name><surname>Kryukov</surname> <given-names>GV</given-names></name><name><surname>Lo</surname> <given-names>CC</given-names></name><name><surname>McDonald</surname> <given-names>ER</given-names></name><name><surname>Barretina</surname> <given-names>J</given-names></name><name><surname>Gelfand</surname> <given-names>ET</given-names></name><name><surname>Bielski</surname> <given-names>CM</given-names></name><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Hu</surname> <given-names>K</given-names></name><name><surname>Andreev-Drakhlin</surname> <given-names>AY</given-names></name><name><surname>Kim</surname> <given-names>J</given-names></name><name><surname>Hess</surname> <given-names>JM</given-names></name><name><surname>Haas</surname> <given-names>BJ</given-names></name><name><surname>Aguet</surname> <given-names>F</given-names></name><name><surname>Weir</surname> <given-names>BA</given-names></name><name><surname>Rothberg</surname> <given-names>MV</given-names></name><name><surname>Paolella</surname> <given-names>BR</given-names></name><name><surname>Lawrence</surname> <given-names>MS</given-names></name><name><surname>Akbani</surname> <given-names>R</given-names></name><name><surname>Lu</surname> <given-names>Y</given-names></name><name><surname>Tiv</surname> <given-names>HL</given-names></name><name><surname>Gokhale</surname> <given-names>PC</given-names></name><name><surname>de Weck</surname> <given-names>A</given-names></name><name><surname>Mansour</surname> <given-names>AA</given-names></name><name><surname>Oh</surname> <given-names>C</given-names></name><name><surname>Shih</surname> <given-names>J</given-names></name><name><surname>Hadi</surname> <given-names>K</given-names></name><name><surname>Rosen</surname> <given-names>Y</given-names></name><name><surname>Bistline</surname> <given-names>J</given-names></name><name><surname>Venkatesan</surname> <given-names>K</given-names></name><name><surname>Reddy</surname> <given-names>A</given-names></name><name><surname>Sonkin</surname> <given-names>D</given-names></name><name><surname>Liu</surname> <given-names>M</given-names></name><name><surname>Lehar</surname> <given-names>J</given-names></name><name><surname>Korn</surname> <given-names>JM</given-names></name><name><surname>Porter</surname> <given-names>DA</given-names></name><name><surname>Jones</surname> <given-names>MD</given-names></name><name><surname>Golji</surname> <given-names>J</given-names></name><name><surname>Caponigro</surname> <given-names>G</given-names></name><name><surname>Taylor</surname> <given-names>JE</given-names></name><name><surname>Dunning</surname> <given-names>CM</given-names></name><name><surname>Creech</surname> <given-names>AL</given-names></name><name><surname>Warren</surname> <given-names>AC</given-names></name><name><surname>McFarland</surname> <given-names>JM</given-names></name><name><surname>Zamanighomi</surname> <given-names>M</given-names></name><name><surname>Kauffmann</surname> <given-names>A</given-names></name><name><surname>Stransky</surname> <given-names>N</given-names></name><name><surname>Imielinski</surname> <given-names>M</given-names></name><name><surname>Maruvka</surname> <given-names>YE</given-names></name><name><surname>Cherniack</surname> <given-names>AD</given-names></name><name><surname>Tsherniak</surname> <given-names>A</given-names></name><name><surname>Vazquez</surname> <given-names>F</given-names></name><name><surname>Jaffe</surname> <given-names>JD</given-names></name><name><surname>Lane</surname> <given-names>AA</given-names></name><name><surname>Weinstock</surname> <given-names>DM</given-names></name><name><surname>Johannessen</surname> <given-names>CM</given-names></name><name><surname>Morrissey</surname> <given-names>MP</given-names></name><name><surname>Stegmeier</surname> <given-names>F</given-names></name><name><surname>Schlegel</surname> <given-names>R</given-names></name><name><surname>Hahn</surname> <given-names>WC</given-names></name><name><surname>Getz</surname> <given-names>G</given-names></name><name><surname>Mills</surname> <given-names>GB</given-names></name><name><surname>Boehm</surname> <given-names>JS</given-names></name><name><surname>Golub</surname> <given-names>TR</given-names></name><name><surname>Garraway</surname> <given-names>LA</given-names></name><name><surname>Sellers</surname> <given-names>WR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Next-generation characterization of the Cancer cell line encyclopedia</article-title><source>Nature</source><volume>569</volume><fpage>503</fpage><lpage>508</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1186-3</pub-id><pub-id pub-id-type="pmid">31068700</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glaspy</surname> <given-names>J</given-names></name><name><surname>Atkins</surname> <given-names>MB</given-names></name><name><surname>Richards</surname> <given-names>JM</given-names></name><name><surname>Agarwala</surname> <given-names>SS</given-names></name><name><surname>O'Day</surname> <given-names>S</given-names></name><name><surname>Knight</surname> <given-names>RD</given-names></name><name><surname>Jungnelius</surname> <given-names>JU</given-names></name><name><surname>Bedikian</surname> <given-names>AY</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma</article-title><source>Cancer</source><volume>115</volume><fpage>5228</fpage><lpage>5236</lpage><pub-id pub-id-type="doi">10.1002/cncr.24576</pub-id><pub-id pub-id-type="pmid">19728370</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haibe-Kains</surname> <given-names>B</given-names></name><name><surname>El-Hachem</surname> <given-names>N</given-names></name><name><surname>Birkbak</surname> <given-names>NJ</given-names></name><name><surname>Jin</surname> <given-names>AC</given-names></name><name><surname>Beck</surname> <given-names>AH</given-names></name><name><surname>Aerts</surname> <given-names>HJ</given-names></name><name><surname>Quackenbush</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Inconsistency in large pharmacogenomic studies</article-title><source>Nature</source><volume>504</volume><fpage>389</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.1038/nature12831</pub-id><pub-id pub-id-type="pmid">24284626</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haverty</surname> <given-names>PM</given-names></name><name><surname>Lin</surname> <given-names>E</given-names></name><name><surname>Tan</surname> <given-names>J</given-names></name><name><surname>Yu</surname> <given-names>Y</given-names></name><name><surname>Lam</surname> <given-names>B</given-names></name><name><surname>Lianoglou</surname> <given-names>S</given-names></name><name><surname>Neve</surname> <given-names>RM</given-names></name><name><surname>Martin</surname> <given-names>S</given-names></name><name><surname>Settleman</surname> <given-names>J</given-names></name><name><surname>Yauch</surname> <given-names>RL</given-names></name><name><surname>Bourgon</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Reproducible pharmacogenomic profiling of cancer cell line panels</article-title><source>Nature</source><volume>533</volume><fpage>333</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1038/nature17987</pub-id><pub-id pub-id-type="pmid">27193678</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Hensman</surname> <given-names>J</given-names></name><name><surname>Fusi</surname> <given-names>N</given-names></name><name><surname>Lawrence</surname> <given-names>ND</given-names></name></person-group><year iso-8601-date="2013">2013</year><chapter-title>Proceedings of the Twenty-Ninth Conference on Uncertainty in Artificial Intelligence, UAI’13</chapter-title><person-group person-group-type="editor"><name><surname>Hensman</surname> <given-names>J</given-names></name></person-group><source>Gaussian Processes for Big Data</source><publisher-name>AUAI Press</publisher-name><fpage>282</fpage><lpage>290</lpage></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hie</surname> <given-names>B</given-names></name><name><surname>Bryson</surname> <given-names>BD</given-names></name><name><surname>Berger</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Leveraging uncertainty in machine learning accelerates biological discovery and design</article-title><source>Cell Systems</source><volume>11</volume><fpage>461</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1016/j.cels.2020.09.007</pub-id><pub-id pub-id-type="pmid">33065027</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodis</surname> <given-names>E</given-names></name><name><surname>Watson</surname> <given-names>IR</given-names></name><name><surname>Kryukov</surname> <given-names>GV</given-names></name><name><surname>Arold</surname> <given-names>ST</given-names></name><name><surname>Imielinski</surname> <given-names>M</given-names></name><name><surname>Theurillat</surname> <given-names>JP</given-names></name><name><surname>Nickerson</surname> <given-names>E</given-names></name><name><surname>Auclair</surname> <given-names>D</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Place</surname> <given-names>C</given-names></name><name><surname>Dicara</surname> <given-names>D</given-names></name><name><surname>Ramos</surname> <given-names>AH</given-names></name><name><surname>Lawrence</surname> <given-names>MS</given-names></name><name><surname>Cibulskis</surname> <given-names>K</given-names></name><name><surname>Sivachenko</surname> <given-names>A</given-names></name><name><surname>Voet</surname> <given-names>D</given-names></name><name><surname>Saksena</surname> <given-names>G</given-names></name><name><surname>Stransky</surname> <given-names>N</given-names></name><name><surname>Onofrio</surname> <given-names>RC</given-names></name><name><surname>Winckler</surname> <given-names>W</given-names></name><name><surname>Ardlie</surname> <given-names>K</given-names></name><name><surname>Wagle</surname> <given-names>N</given-names></name><name><surname>Wargo</surname> <given-names>J</given-names></name><name><surname>Chong</surname> <given-names>K</given-names></name><name><surname>Morton</surname> <given-names>DL</given-names></name><name><surname>Stemke-Hale</surname> <given-names>K</given-names></name><name><surname>Chen</surname> <given-names>G</given-names></name><name><surname>Noble</surname> <given-names>M</given-names></name><name><surname>Meyerson</surname> <given-names>M</given-names></name><name><surname>Ladbury</surname> <given-names>JE</given-names></name><name><surname>Davies</surname> <given-names>MA</given-names></name><name><surname>Gershenwald</surname> <given-names>JE</given-names></name><name><surname>Wagner</surname> <given-names>SN</given-names></name><name><surname>Hoon</surname> <given-names>DS</given-names></name><name><surname>Schadendorf</surname> <given-names>D</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Gabriel</surname> <given-names>SB</given-names></name><name><surname>Getz</surname> <given-names>G</given-names></name><name><surname>Garraway</surname> <given-names>LA</given-names></name><name><surname>Chin</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A landscape of driver mutations in melanoma</article-title><source>Cell</source><volume>150</volume><fpage>251</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.06.024</pub-id><pub-id pub-id-type="pmid">22817889</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holbeck</surname> <given-names>SL</given-names></name><name><surname>Camalier</surname> <given-names>R</given-names></name><name><surname>Crowell</surname> <given-names>JA</given-names></name><name><surname>Govindharajulu</surname> <given-names>JP</given-names></name><name><surname>Hollingshead</surname> <given-names>M</given-names></name><name><surname>Anderson</surname> <given-names>LW</given-names></name><name><surname>Polley</surname> <given-names>E</given-names></name><name><surname>Rubinstein</surname> <given-names>L</given-names></name><name><surname>Srivastava</surname> <given-names>A</given-names></name><name><surname>Wilsker</surname> <given-names>D</given-names></name><name><surname>Collins</surname> <given-names>JM</given-names></name><name><surname>Doroshow</surname> <given-names>JH</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The national Cancer institute ALMANAC: a comprehensive screening resource for the detection of anticancer drug pairs with enhanced therapeutic activity</article-title><source>Cancer Research</source><volume>77</volume><fpage>3564</fpage><lpage>3576</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-17-0489</pub-id><pub-id pub-id-type="pmid">28446463</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iorio</surname> <given-names>F</given-names></name><name><surname>Knijnenburg</surname> <given-names>TA</given-names></name><name><surname>Vis</surname> <given-names>DJ</given-names></name><name><surname>Bignell</surname> <given-names>GR</given-names></name><name><surname>Menden</surname> <given-names>MP</given-names></name><name><surname>Schubert</surname> <given-names>M</given-names></name><name><surname>Aben</surname> <given-names>N</given-names></name><name><surname>Gonçalves</surname> <given-names>E</given-names></name><name><surname>Barthorpe</surname> <given-names>S</given-names></name><name><surname>Lightfoot</surname> <given-names>H</given-names></name><name><surname>Cokelaer</surname> <given-names>T</given-names></name><name><surname>Greninger</surname> <given-names>P</given-names></name><name><surname>van Dyk</surname> <given-names>E</given-names></name><name><surname>Chang</surname> <given-names>H</given-names></name><name><surname>de Silva</surname> <given-names>H</given-names></name><name><surname>Heyn</surname> <given-names>H</given-names></name><name><surname>Deng</surname> <given-names>X</given-names></name><name><surname>Egan</surname> <given-names>RK</given-names></name><name><surname>Liu</surname> <given-names>Q</given-names></name><name><surname>Mironenko</surname> <given-names>T</given-names></name><name><surname>Mitropoulos</surname> <given-names>X</given-names></name><name><surname>Richardson</surname> <given-names>L</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>T</given-names></name><name><surname>Moran</surname> <given-names>S</given-names></name><name><surname>Sayols</surname> <given-names>S</given-names></name><name><surname>Soleimani</surname> <given-names>M</given-names></name><name><surname>Tamborero</surname> <given-names>D</given-names></name><name><surname>Lopez-Bigas</surname> <given-names>N</given-names></name><name><surname>Ross-Macdonald</surname> <given-names>P</given-names></name><name><surname>Esteller</surname> <given-names>M</given-names></name><name><surname>Gray</surname> <given-names>NS</given-names></name><name><surname>Haber</surname> <given-names>DA</given-names></name><name><surname>Stratton</surname> <given-names>MR</given-names></name><name><surname>Benes</surname> <given-names>CH</given-names></name><name><surname>Wessels</surname> <given-names>LFA</given-names></name><name><surname>Saez-Rodriguez</surname> <given-names>J</given-names></name><name><surname>McDermott</surname> <given-names>U</given-names></name><name><surname>Garnett</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A landscape of pharmacogenomic interactions in Cancer</article-title><source>Cell</source><volume>166</volume><fpage>740</fpage><lpage>754</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.06.017</pub-id><pub-id pub-id-type="pmid">27397505</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname> <given-names>X</given-names></name><name><surname>Mo</surname> <given-names>Q</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Gao</surname> <given-names>Y</given-names></name><name><surname>Wu</surname> <given-names>Y</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Hao</surname> <given-names>X</given-names></name><name><surname>Ma</surname> <given-names>D</given-names></name><name><surname>Gao</surname> <given-names>Q</given-names></name><name><surname>Chen</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The p38 MAPK inhibitor BIRB796 enhances the antitumor effects of VX680 in cervical Cancer</article-title><source>Cancer Biology &amp; Therapy</source><volume>17</volume><fpage>566</fpage><lpage>576</lpage><pub-id pub-id-type="doi">10.1080/15384047.2016.1177676</pub-id><pub-id pub-id-type="pmid">27082306</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keshava</surname> <given-names>N</given-names></name><name><surname>Toh</surname> <given-names>TS</given-names></name><name><surname>Yuan</surname> <given-names>H</given-names></name><name><surname>Yang</surname> <given-names>B</given-names></name><name><surname>Menden</surname> <given-names>MP</given-names></name><name><surname>Wang</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Defining subpopulations of differential drug response to reveal novel target populations</article-title><source>Npj Systems Biology and Applications</source><volume>5</volume><elocation-id>36</elocation-id><pub-id pub-id-type="doi">10.1038/s41540-019-0113-4</pub-id><pub-id pub-id-type="pmid">31602313</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Konecny</surname> <given-names>GE</given-names></name><name><surname>Pegram</surname> <given-names>MD</given-names></name><name><surname>Venkatesan</surname> <given-names>N</given-names></name><name><surname>Finn</surname> <given-names>R</given-names></name><name><surname>Yang</surname> <given-names>G</given-names></name><name><surname>Rahmeh</surname> <given-names>M</given-names></name><name><surname>Untch</surname> <given-names>M</given-names></name><name><surname>Rusnak</surname> <given-names>DW</given-names></name><name><surname>Spehar</surname> <given-names>G</given-names></name><name><surname>Mullin</surname> <given-names>RJ</given-names></name><name><surname>Keith</surname> <given-names>BR</given-names></name><name><surname>Gilmer</surname> <given-names>TM</given-names></name><name><surname>Berger</surname> <given-names>M</given-names></name><name><surname>Podratz</surname> <given-names>KC</given-names></name><name><surname>Slamon</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast Cancer cells</article-title><source>Cancer Research</source><volume>66</volume><fpage>1630</fpage><lpage>1639</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-1182</pub-id><pub-id pub-id-type="pmid">16452222</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kopetz</surname> <given-names>S</given-names></name><name><surname>Grothey</surname> <given-names>A</given-names></name><name><surname>Yaeger</surname> <given-names>R</given-names></name><name><surname>Van Cutsem</surname> <given-names>E</given-names></name><name><surname>Desai</surname> <given-names>J</given-names></name><name><surname>Yoshino</surname> <given-names>T</given-names></name><name><surname>Wasan</surname> <given-names>H</given-names></name><name><surname>Ciardiello</surname> <given-names>F</given-names></name><name><surname>Loupakis</surname> <given-names>F</given-names></name><name><surname>Hong</surname> <given-names>YS</given-names></name><name><surname>Steeghs</surname> <given-names>N</given-names></name><name><surname>Guren</surname> <given-names>TK</given-names></name><name><surname>Arkenau</surname> <given-names>HT</given-names></name><name><surname>Garcia-Alfonso</surname> <given-names>P</given-names></name><name><surname>Pfeiffer</surname> <given-names>P</given-names></name><name><surname>Orlov</surname> <given-names>S</given-names></name><name><surname>Lonardi</surname> <given-names>S</given-names></name><name><surname>Elez</surname> <given-names>E</given-names></name><name><surname>Kim</surname> <given-names>TW</given-names></name><name><surname>Schellens</surname> <given-names>JHM</given-names></name><name><surname>Guo</surname> <given-names>C</given-names></name><name><surname>Krishnan</surname> <given-names>A</given-names></name><name><surname>Dekervel</surname> <given-names>J</given-names></name><name><surname>Morris</surname> <given-names>V</given-names></name><name><surname>Calvo Ferrandiz</surname> <given-names>A</given-names></name><name><surname>Tarpgaard</surname> <given-names>LS</given-names></name><name><surname>Braun</surname> <given-names>M</given-names></name><name><surname>Gollerkeri</surname> <given-names>A</given-names></name><name><surname>Keir</surname> <given-names>C</given-names></name><name><surname>Maharry</surname> <given-names>K</given-names></name><name><surname>Pickard</surname> <given-names>M</given-names></name><name><surname>Christy-Bittel</surname> <given-names>J</given-names></name><name><surname>Anderson</surname> <given-names>L</given-names></name><name><surname>Sandor</surname> <given-names>V</given-names></name><name><surname>Tabernero</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Encorafenib, Binimetinib, and cetuximab in <italic>BRAF</italic> V600E-Mutated colorectal Cancer</article-title><source>New England Journal of Medicine</source><volume>381</volume><fpage>1632</fpage><lpage>1643</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1908075</pub-id><pub-id pub-id-type="pmid">31566309</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez-Lopera</surname> <given-names>AF</given-names></name><name><surname>Alvarez</surname> <given-names>MA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Switched latent force models for Reverse-Engineering transcriptional regulation in gene expression data</article-title><source>IEEE/ACM Transactions on Computational Biology and Bioinformatics</source><volume>16</volume><fpage>322</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1109/TCBB.2017.2764908</pub-id><pub-id pub-id-type="pmid">29990003</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lucena-Cacace</surname> <given-names>A</given-names></name><name><surname>Otero-Albiol</surname> <given-names>D</given-names></name><name><surname>Jiménez-García</surname> <given-names>MP</given-names></name><name><surname>Peinado-Serrano</surname> <given-names>J</given-names></name><name><surname>Carnero</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>NAMPT overexpression induces cancer stemness and defines a novel tumor signature for glioma prognosis</article-title><source>Oncotarget</source><volume>8</volume><fpage>99514</fpage><lpage>99530</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.20577</pub-id><pub-id pub-id-type="pmid">29245920</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lucena-Cacace</surname> <given-names>A</given-names></name><name><surname>Umeda</surname> <given-names>M</given-names></name><name><surname>Navas</surname> <given-names>LE</given-names></name><name><surname>Carnero</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>NAMPT as a Dedifferentiation-Inducer gene: nad<sup>+</sup> as Core Axis for Glioma Cancer Stem-Like Cells Maintenance</article-title><source>Frontiers in Oncology</source><volume>9</volume><elocation-id>292</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2019.00292</pub-id><pub-id pub-id-type="pmid">31119097</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Inhibitors of protein methyltransferases as chemical tools</article-title><source>Epigenomics</source><volume>7</volume><fpage>1327</fpage><lpage>1338</lpage><pub-id pub-id-type="doi">10.2217/epi.15.87</pub-id><pub-id pub-id-type="pmid">26646500</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matthews AG de</surname> <given-names>G</given-names></name><name><surname>van der Wilk</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>GPflow: A Gaussian process library using TensorFlow</article-title><source>Journal of Machine Learning Research</source><volume>18</volume><fpage>1</fpage><lpage>6</lpage></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menden</surname> <given-names>MP</given-names></name><name><surname>Wang</surname> <given-names>D</given-names></name><name><surname>Mason</surname> <given-names>MJ</given-names></name><name><surname>Szalai</surname> <given-names>B</given-names></name><name><surname>Bulusu</surname> <given-names>KC</given-names></name><name><surname>Guan</surname> <given-names>Y</given-names></name><name><surname>Yu</surname> <given-names>T</given-names></name><name><surname>Kang</surname> <given-names>J</given-names></name><name><surname>Jeon</surname> <given-names>M</given-names></name><name><surname>Wolfinger</surname> <given-names>R</given-names></name><name><surname>Nguyen</surname> <given-names>T</given-names></name><name><surname>Zaslavskiy</surname> <given-names>M</given-names></name><name><surname>Jang</surname> <given-names>IS</given-names></name><name><surname>Ghazoui</surname> <given-names>Z</given-names></name><name><surname>Ahsen</surname> <given-names>ME</given-names></name><name><surname>Vogel</surname> <given-names>R</given-names></name><name><surname>Neto</surname> <given-names>EC</given-names></name><name><surname>Norman</surname> <given-names>T</given-names></name><name><surname>Tang</surname> <given-names>EKY</given-names></name><name><surname>Garnett</surname> <given-names>MJ</given-names></name><name><surname>Veroli</surname> <given-names>GYD</given-names></name><name><surname>Fawell</surname> <given-names>S</given-names></name><name><surname>Stolovitzky</surname> <given-names>G</given-names></name><name><surname>Guinney</surname> <given-names>J</given-names></name><name><surname>Dry</surname> <given-names>JR</given-names></name><name><surname>Saez-Rodriguez</surname> <given-names>J</given-names></name><collab>AstraZeneca-Sanger Drug Combination DREAM Consortium</collab></person-group><year iso-8601-date="2019">2019</year><article-title>Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>2674</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-09799-2</pub-id><pub-id pub-id-type="pmid">31209238</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Neil</surname> <given-names>J</given-names></name><name><surname>Benita</surname> <given-names>Y</given-names></name><name><surname>Feldman</surname> <given-names>I</given-names></name><name><surname>Chenard</surname> <given-names>M</given-names></name><name><surname>Roberts</surname> <given-names>B</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Kral</surname> <given-names>A</given-names></name><name><surname>Lejnine</surname> <given-names>S</given-names></name><name><surname>Loboda</surname> <given-names>A</given-names></name><name><surname>Arthur</surname> <given-names>W</given-names></name><name><surname>Cristescu</surname> <given-names>R</given-names></name><name><surname>Haines</surname> <given-names>BB</given-names></name><name><surname>Winter</surname> <given-names>C</given-names></name><name><surname>Zhang</surname> <given-names>T</given-names></name><name><surname>Bloecher</surname> <given-names>A</given-names></name><name><surname>Shumway</surname> <given-names>SD</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>An unbiased oncology compound screen to identify novel combination strategies</article-title><source>Molecular Cancer Therapeutics</source><volume>15</volume><fpage>1155</fpage><lpage>1162</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-15-0843</pub-id><pub-id pub-id-type="pmid">26983881</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oba</surname> <given-names>A</given-names></name><name><surname>Shimada</surname> <given-names>S</given-names></name><name><surname>Akiyama</surname> <given-names>Y</given-names></name><name><surname>Nishikawaji</surname> <given-names>T</given-names></name><name><surname>Mogushi</surname> <given-names>K</given-names></name><name><surname>Ito</surname> <given-names>H</given-names></name><name><surname>Matsumura</surname> <given-names>S</given-names></name><name><surname>Aihara</surname> <given-names>A</given-names></name><name><surname>Mitsunori</surname> <given-names>Y</given-names></name><name><surname>Ban</surname> <given-names>D</given-names></name><name><surname>Ochiai</surname> <given-names>T</given-names></name><name><surname>Kudo</surname> <given-names>A</given-names></name><name><surname>Asahara</surname> <given-names>H</given-names></name><name><surname>Kaida</surname> <given-names>A</given-names></name><name><surname>Miura</surname> <given-names>M</given-names></name><name><surname>Tanabe</surname> <given-names>M</given-names></name><name><surname>Tanaka</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>ARID2 modulates DNA damage response in human hepatocellular carcinoma cells</article-title><source>Journal of Hepatology</source><volume>66</volume><fpage>942</fpage><lpage>951</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2016.12.026</pub-id><pub-id pub-id-type="pmid">28238438</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prahallad</surname> <given-names>A</given-names></name><name><surname>Sun</surname> <given-names>C</given-names></name><name><surname>Huang</surname> <given-names>S</given-names></name><name><surname>Di Nicolantonio</surname> <given-names>F</given-names></name><name><surname>Salazar</surname> <given-names>R</given-names></name><name><surname>Zecchin</surname> <given-names>D</given-names></name><name><surname>Beijersbergen</surname> <given-names>RL</given-names></name><name><surname>Bardelli</surname> <given-names>A</given-names></name><name><surname>Bernards</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR</article-title><source>Nature</source><volume>483</volume><fpage>100</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1038/nature10868</pub-id><pub-id pub-id-type="pmid">22281684</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Rasmussen</surname> <given-names>CE</given-names></name><name><surname>Williams</surname> <given-names>CKI</given-names></name></person-group><year iso-8601-date="2005">2005</year><source>Gaussian Processes for Machine Learning</source><publisher-loc>Massachusetts, United States</publisher-loc><publisher-name>MIT Press</publisher-name></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rees</surname> <given-names>MG</given-names></name><name><surname>Seashore-Ludlow</surname> <given-names>B</given-names></name><name><surname>Cheah</surname> <given-names>JH</given-names></name><name><surname>Adams</surname> <given-names>DJ</given-names></name><name><surname>Price</surname> <given-names>EV</given-names></name><name><surname>Gill</surname> <given-names>S</given-names></name><name><surname>Javaid</surname> <given-names>S</given-names></name><name><surname>Coletti</surname> <given-names>ME</given-names></name><name><surname>Jones</surname> <given-names>VL</given-names></name><name><surname>Bodycombe</surname> <given-names>NE</given-names></name><name><surname>Soule</surname> <given-names>CK</given-names></name><name><surname>Alexander</surname> <given-names>B</given-names></name><name><surname>Li</surname> <given-names>A</given-names></name><name><surname>Montgomery</surname> <given-names>P</given-names></name><name><surname>Kotz</surname> <given-names>JD</given-names></name><name><surname>Hon</surname> <given-names>CS</given-names></name><name><surname>Munoz</surname> <given-names>B</given-names></name><name><surname>Liefeld</surname> <given-names>T</given-names></name><name><surname>Dančík</surname> <given-names>V</given-names></name><name><surname>Haber</surname> <given-names>DA</given-names></name><name><surname>Clish</surname> <given-names>CB</given-names></name><name><surname>Bittker</surname> <given-names>JA</given-names></name><name><surname>Palmer</surname> <given-names>M</given-names></name><name><surname>Wagner</surname> <given-names>BK</given-names></name><name><surname>Clemons</surname> <given-names>PA</given-names></name><name><surname>Shamji</surname> <given-names>AF</given-names></name><name><surname>Schreiber</surname> <given-names>SL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Correlating chemical sensitivity and basal gene expression reveals mechanism of action</article-title><source>Nature Chemical Biology</source><volume>12</volume><fpage>109</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1038/nchembio.1986</pub-id><pub-id pub-id-type="pmid">26656090</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Riihimäki</surname> <given-names>J</given-names></name><name><surname>Vehtari</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Gaussian processes with monotonicity information</article-title><conf-name>Proceedings of the Thirteenth International Conference on Artificial Intelligence and Statistics</conf-name><fpage>645</fpage><lpage>652</lpage></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seashore-Ludlow</surname> <given-names>B</given-names></name><name><surname>Rees</surname> <given-names>MG</given-names></name><name><surname>Cheah</surname> <given-names>JH</given-names></name><name><surname>Cokol</surname> <given-names>M</given-names></name><name><surname>Price</surname> <given-names>EV</given-names></name><name><surname>Coletti</surname> <given-names>ME</given-names></name><name><surname>Jones</surname> <given-names>V</given-names></name><name><surname>Bodycombe</surname> <given-names>NE</given-names></name><name><surname>Soule</surname> <given-names>CK</given-names></name><name><surname>Gould</surname> <given-names>J</given-names></name><name><surname>Alexander</surname> <given-names>B</given-names></name><name><surname>Li</surname> <given-names>A</given-names></name><name><surname>Montgomery</surname> <given-names>P</given-names></name><name><surname>Wawer</surname> <given-names>MJ</given-names></name><name><surname>Kuru</surname> <given-names>N</given-names></name><name><surname>Kotz</surname> <given-names>JD</given-names></name><name><surname>Hon</surname> <given-names>CS</given-names></name><name><surname>Munoz</surname> <given-names>B</given-names></name><name><surname>Liefeld</surname> <given-names>T</given-names></name><name><surname>Dančík</surname> <given-names>V</given-names></name><name><surname>Bittker</surname> <given-names>JA</given-names></name><name><surname>Palmer</surname> <given-names>M</given-names></name><name><surname>Bradner</surname> <given-names>JE</given-names></name><name><surname>Shamji</surname> <given-names>AF</given-names></name><name><surname>Clemons</surname> <given-names>PA</given-names></name><name><surname>Schreiber</surname> <given-names>SL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Harnessing connectivity in a Large-Scale Small-Molecule sensitivity dataset</article-title><source>Cancer Discovery</source><volume>5</volume><fpage>1210</fpage><lpage>1223</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-15-0235</pub-id><pub-id pub-id-type="pmid">26482930</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Shi</surname> <given-names>JQ</given-names></name><name><surname>Choi</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2011">2011</year><source>Gaussian Process Regression Analysis for Functional Data</source><publisher-loc>New York, United States</publisher-loc><publisher-name>CRC Press</publisher-name><pub-id pub-id-type="doi">10.1201/b11038</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silverbush</surname> <given-names>D</given-names></name><name><surname>Grosskurth</surname> <given-names>S</given-names></name><name><surname>Wang</surname> <given-names>D</given-names></name><name><surname>Powell</surname> <given-names>F</given-names></name><name><surname>Gottgens</surname> <given-names>B</given-names></name><name><surname>Dry</surname> <given-names>J</given-names></name><name><surname>Fisher</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Cell-Specific computational modeling of the PIM pathway in acute myeloid leukemia</article-title><source>Cancer Research</source><volume>77</volume><fpage>827</fpage><lpage>838</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-16-1578</pub-id><pub-id pub-id-type="pmid">27965317</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Stein</surname> <given-names>ML</given-names></name></person-group><year iso-8601-date="2012">2012</year><source>Interpolation of Spatial Data: Some Theory for Kriging</source><publisher-loc>Berlin, Germany</publisher-loc><publisher-name>Springer Science &amp; Business Media</publisher-name></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamura</surname> <given-names>K</given-names></name><name><surname>Fukuoka</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Gefitinib in non-small cell lung cancer</article-title><source>Expert Opinion on Pharmacotherapy</source><volume>6</volume><fpage>985</fpage><lpage>993</lpage><pub-id pub-id-type="doi">10.1517/14656566.6.6.985</pub-id><pub-id pub-id-type="pmid">15952926</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Tansey</surname> <given-names>W</given-names></name><name><surname>Li</surname> <given-names>K</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Linderman</surname> <given-names>SW</given-names></name><name><surname>Rabadan</surname> <given-names>R</given-names></name><name><surname>Blei</surname> <given-names>DM</given-names></name><name><surname>Wiggins</surname> <given-names>CH</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Dose-response modeling in high-throughput cancer drug screenings: a case study with recommendations for practitioners</article-title><source>arXiv.org</source><ext-link ext-link-type="uri" xlink:href="https://arxiv.org/abs/1812.05691">https://arxiv.org/abs/1812.05691</ext-link></element-citation></ref><ref id="bib46"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Tansey</surname> <given-names>W</given-names></name><name><surname>Tosh</surname> <given-names>C</given-names></name><name><surname>Blei</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Relational Dose-Response modeling for Cancer drug studies</article-title><source>arXiv</source><ext-link ext-link-type="uri" xlink:href="https://arxiv.org/abs/1906.04072">https://arxiv.org/abs/1906.04072</ext-link></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname> <given-names>L</given-names></name><name><surname>Wilkinson</surname> <given-names>R</given-names></name><name><surname>Yang</surname> <given-names>Z</given-names></name><name><surname>Power</surname> <given-names>H</given-names></name><name><surname>Fagerlund</surname> <given-names>F</given-names></name><name><surname>Niemi</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Gaussian process emulators for quantifying uncertainty inCO2spreading predictions in heterogeneous media</article-title><source>Computers &amp; Geosciences</source><volume>105</volume><fpage>113</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1016/j.cageo.2017.04.006</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toh</surname> <given-names>TS</given-names></name><name><surname>Dondelinger</surname> <given-names>F</given-names></name><name><surname>Wang</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Looking beyond the hype: applied AI and machine learning in translational medicine</article-title><source>EBioMedicine</source><volume>47</volume><fpage>607</fpage><lpage>615</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2019.08.027</pub-id><pub-id pub-id-type="pmid">31466916</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vis</surname> <given-names>DJ</given-names></name><name><surname>Bombardelli</surname> <given-names>L</given-names></name><name><surname>Lightfoot</surname> <given-names>H</given-names></name><name><surname>Iorio</surname> <given-names>F</given-names></name><name><surname>Garnett</surname> <given-names>MJ</given-names></name><name><surname>Wessels</surname> <given-names>LF</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Multilevel models improve precision and speed of IC50 estimates</article-title><source>Pharmacogenomics</source><volume>17</volume><fpage>691</fpage><lpage>700</lpage><pub-id pub-id-type="doi">10.2217/pgs.16.15</pub-id><pub-id pub-id-type="pmid">27180993</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vlot</surname> <given-names>AHC</given-names></name><name><surname>Aniceto</surname> <given-names>N</given-names></name><name><surname>Menden</surname> <given-names>MP</given-names></name><name><surname>Ulrich-Merzenich</surname> <given-names>G</given-names></name><name><surname>Bender</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Applying synergy metrics to combination screening data: agreements, disagreements and pitfalls</article-title><source>Drug Discovery Today</source><volume>24</volume><fpage>2286</fpage><lpage>2298</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2019.09.002</pub-id><pub-id pub-id-type="pmid">31518641</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Jadhav</surname> <given-names>A</given-names></name><name><surname>Southal</surname> <given-names>N</given-names></name><name><surname>Huang</surname> <given-names>R</given-names></name><name><surname>Nguyen</surname> <given-names>DT</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A grid algorithm for high throughput fitting of dose-response curve data</article-title><source>Current Chemical Genomics</source><volume>4</volume><fpage>57</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.2174/1875397301004010057</pub-id><pub-id pub-id-type="pmid">21331310</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>JC-H</given-names></name><name><surname>Schuler</surname> <given-names>MH</given-names></name><name><surname>Yamamoto</surname> <given-names>N</given-names></name><name><surname>O'Byrne</surname> <given-names>KJ</given-names></name><name><surname>Hirsh</surname> <given-names>V</given-names></name><name><surname>Mok</surname> <given-names>T</given-names></name><name><surname>Geater</surname> <given-names>SL</given-names></name><name><surname>Orlov</surname> <given-names>SV</given-names></name><name><surname>Tsai</surname> <given-names>C-M</given-names></name><name><surname>Boyer</surname> <given-names>MJ</given-names></name><name><surname>Su</surname> <given-names>W-C</given-names></name><name><surname>Bennouna</surname> <given-names>J</given-names></name><name><surname>Kato</surname> <given-names>T</given-names></name><name><surname>Gorbunova</surname> <given-names>V</given-names></name><name><surname>Lee</surname> <given-names>KH</given-names></name><name><surname>Shah</surname> <given-names>RNH</given-names></name><name><surname>Massey</surname> <given-names>D</given-names></name><name><surname>Lorence</surname> <given-names>RM</given-names></name><name><surname>Shahidi</surname> <given-names>M</given-names></name><name><surname>Sequist</surname> <given-names>LV</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>LUX-Lung 3: a randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations</article-title><source>Journal of Clinical Oncology</source><volume>30</volume><elocation-id>LBA7500</elocation-id><pub-id pub-id-type="doi">10.1200/jco.2012.30.15_suppl.lba7500</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yasui</surname> <given-names>H</given-names></name><name><surname>Hideshima</surname> <given-names>T</given-names></name><name><surname>Ikeda</surname> <given-names>H</given-names></name><name><surname>Jin</surname> <given-names>J</given-names></name><name><surname>Ocio</surname> <given-names>EM</given-names></name><name><surname>Kiziltepe</surname> <given-names>T</given-names></name><name><surname>Okawa</surname> <given-names>Y</given-names></name><name><surname>Vallet</surname> <given-names>S</given-names></name><name><surname>Podar</surname> <given-names>K</given-names></name><name><surname>Ishitsuka</surname> <given-names>K</given-names></name><name><surname>Richardson</surname> <given-names>PG</given-names></name><name><surname>Pargellis</surname> <given-names>C</given-names></name><name><surname>Moss</surname> <given-names>N</given-names></name><name><surname>Raje</surname> <given-names>N</given-names></name><name><surname>Anderson</surname> <given-names>KC</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth</article-title><source>British Journal of Haematology</source><volume>136</volume><fpage>414</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2141.2006.06443.x</pub-id><pub-id pub-id-type="pmid">17173546</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>LY</given-names></name><name><surname>Liu</surname> <given-names>LY</given-names></name><name><surname>Qie</surname> <given-names>LL</given-names></name><name><surname>Ling</surname> <given-names>KN</given-names></name><name><surname>Xu</surname> <given-names>LH</given-names></name><name><surname>Wang</surname> <given-names>F</given-names></name><name><surname>Fang</surname> <given-names>SH</given-names></name><name><surname>Lu</surname> <given-names>YB</given-names></name><name><surname>Hu</surname> <given-names>H</given-names></name><name><surname>Wei</surname> <given-names>EQ</given-names></name><name><surname>Zhang</surname> <given-names>WP</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Anti-proliferation effect of APO866 on C6 glioblastoma cells by inhibiting nicotinamide phosphoribosyltransferase</article-title><source>European Journal of Pharmacology</source><volume>674</volume><fpage>163</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2011.11.017</pub-id><pub-id pub-id-type="pmid">22119381</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.60352.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Lehár</surname><given-names>Joseph</given-names></name><role>Reviewing Editor</role><aff><institution>Boyce Thompson Institute for Plant Research</institution><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Blocker</surname><given-names>Alexander W</given-names></name><role>Reviewer</role><aff><institution/></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>This manuscript presents two statistical approaches to evaluating for drug effect measurements and associations between biomarkers, for dose curve data. Measurements of these kinds are made in many contexts, and frequently reported without accounting well for measurement uncertainties. A statistical framework of this kind will be widely useful and should be frequently applied.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;A statistical framework for assessing pharmacological response and biomarkers using uncertainty estimates&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Detlef Weigel as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Alexander W Blocker (Reviewer #1).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, we are asking editors to accept without delay manuscripts, like yours, that they judge can stand as <italic>eLife</italic> papers without additional data, even if they feel that they would make the manuscript stronger. Thus the revisions requested below only address clarity and presentation.</p><p>This manuscript presents two statistical approaches to evaluating for drug effect measurements and associations between biomarkers, for dose curve data. Measurements of these kinds are made in many contexts, and frequently reported without accounting well for measurement uncertainties. A statistical framework of this kind will be widely useful and should be frequently applied.</p><p>The reviewers noted some issues with in the manuscript, which should be addressed before final acceptance to <italic>eLife</italic>.</p><p>Essential revisions:</p><p>1) While this work presents a clear statistical framework, the Discussion and Abstract should explain more clearly how this framework improves drug potency or biomarker discovery efforts. That will help communicate the relevance of this work.</p><p>2) The authors should clarify of how measurement errors in the curves relate to fitted parameter uncertainties, to explain the superiority of particular fitting approaches.</p><p>3) A more thorough discussion of fitting performance is recommended. In particular, accounting for how fitting parameter selection and degrees of freedom. It would also be helpful to explore robust estimators to assess the reliability of fitted parameters. A more thorough analysis is also recommended for edge cases where the IC<sub>50</sub> falls outside the measured range.</p><p>4) Additional model checking and comparisons would be useful. For example, Comparing the presented models to a more standard sigmoid, and additional comparisons highlighted in the comments. It would also help to clarify the relationship between Bayesian posterior probabilities, and ANOVA q-values for the GP approach.</p><p>5) The authors should revise Figure 3C and D. Grouping response curves by mechanism can be misleading since different drugs or biomarkers may intrinsically have discordant potencies due to differing on-target binding efficiency or off-target effects.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.60352.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) While this work presents a clear statistical framework, the Discussion and Abstract should explain more clearly how this framework improves drug potency or biomarker discovery efforts. That will help communicate the relevance of this work.</p></disp-quote><p>We have highlighted the utility of our framework for identifying new biomarkers and highlighting drugs with more potency by putting more weight on cases with lower uncertainty in the statistical models as well as generalised to other diseases. We have edited the Abstract:</p><p>“High-throughput testing of drugs across molecular-characterised cell lines can identify candidate treatments and discover biomarkers. […] Our method is applicable to any dose-response data without replicates, and improves biomarker discovery for precision medicine.”</p><p>and added the following section in the Discussion to communicate this:</p><p>“The increasing utilisation of high-throughput drug screening for identifying effective new treatments will necessitate the use of more powerful statistical and machine learning methods (Toh et al., 2019). […] We hope that by considering response uncertainty and providing a probabilistic view of drug biomarkers, the risks associated with drug development can be better balanced and smarter decisions can be made.”</p><disp-quote content-type="editor-comment"><p>2) The authors should clarify of how measurement errors in the curves relate to fitted parameter uncertainties, to explain the superiority of particular fitting approaches.</p></disp-quote><p>First of all, we would like to clarify the term ‘estimation uncertainty’ in the context of our method. This is not related to between-sample dispersion; due to the high-throughput nature of the GDSC assays, no technical or biological replicates were generated, with the exception of the replicate dataset described in Figure 2 for quality control. Hence the estimation uncertainty refers to the standard deviation of summary measures estimated from a single sample. Here, we capture the dispersion of the posterior distribution of these summary measures. If the dispersion is large, then we will have less confidence in the estimated mean value of the summary measure. Measurement errors for individual points on the dose-response curve will generally result in larger estimation uncertainty. We have added a clarification in the Results section:</p><p>“When the estimation uncertainty is large, we will have less confidence in the estimated IC<sub>50</sub> in an experiment. Measurement errors for individual points in a dose-response curve will generally result in larger estimation uncertainty, whereas greater variation between biological replicates will result in larger observation uncertainty.”</p><p>Also in Figure 2, we have provided a detailed comparison between this estimation uncertainty and the observation uncertainty that can be measured by estimating summary values for multiple biological replicates. We observe that for the estimation of IC<sub>50</sub> values, observation uncertainty is strongly positively correlated (r=0.84) with estimation uncertainty when the IC<sub>50</sub> value is within the dosage range, but for values outside the dosage range, the estimation uncertainty increases, while the observation uncertainty decreases. This indicates that estimation uncertainty is reflective of the true uncertainty in the estimate when the relevant summary statistic (IC<sub>50</sub>) can be determined from the measured dosages alone, but for estimating statistics that require extrapolation beyond the maximum dosage, we would additionally need to take the observation uncertainty into account. We addressed this in the Discussion section by adding this text:</p><p>“We are interested in the former to assess the quality of the fit, and therefore the reliability of the estimated IC<sub>50</sub>. […] Instead, our method defines a very large confidence interval for drug response statistics extrapolated beyond the maximum dose tested and we would additionally need to take the observation uncertainty between replicate experiments into account.”</p><disp-quote content-type="editor-comment"><p>3) A more thorough discussion of fitting performance is recommended. In particular, accounting for how fitting parameter selection and degrees of freedom.</p></disp-quote><p>We have added a more detailed discussion and suggestions for selecting GP fitting parameters in the Materials and methods section:</p><p>“Hyperparameters for the GP model were determined by manual tuning; however, for other datasets, we could also envision a Bayesian model selection procedure which places the variational inference in a variational-within-MCMC scheme where the MCMC moves update the hyperparameters. […] To avoid massive computational complexity, the MCMC scheme could be run on a representative subsample of cell lines.”</p><p>We also added suggestions for how the hyperparameter in the Bayesian biomarker model can be tuned:</p><p>“The main tuneable hyperparameter is the scaling parameter c, as the model is robust to changes to the parameters for the sparse priors on <italic>β</italic> and <italic>σ</italic><sup>*2</sup>. […] One way to determine the optimal value for c is to randomly permute the biomarker labels, and reduce c until the false positive rate is below some acceptable threshold.”</p><disp-quote content-type="editor-comment"><p>It would also be helpful to explore robust estimators to assess the reliability of fitted parameters.</p></disp-quote><p>We agree it would be useful to assess the reliability of the fitted parameters to understand whether the performance of our GP model stemmed from correcting misspecification in original ANOVA, or the use of uncertainty estimates. Like the reviewer, we wondered whether heteroskedasticity of the IC<sub>50</sub> estimates impacted performance, so we performed our biomarker association testing using the AUCs of the fitted curves, hence AUC values display a homoscedastic behaviour. For this, we show that the uncertainty estimates from the AUCs did not vary across doses like IC<sub>50</sub> uncertainties (new Figure 4—figure supplement 1A-D). We also show the difference in biomarker associations between sigmoid and GP curve fits (Figure 4—figure supplement 1E, F), and show that we recovered all 26 gold standard biomarkers and additional sensitivity biomarkers using AUCs (Figure 4—figure supplement 1G). These new findings have been added to the Results section:</p><p>“Alternatively, AUC values can be used to compare both curve fitting methods (Figure 4—figure supplement 1). While known clinical biomarkers are recovered with AUC as a drug response metric, IC<sub>50</sub> measures were used in the subsequent analysis as they retain direct relationship with the drug concentration and are more interpretable.”</p><disp-quote content-type="editor-comment"><p>A more thorough analysis is also recommended for edge cases where the IC<sub>50</sub> falls outside the measured range.</p></disp-quote><p>We have highlighted the analysis we conducted in Figure 2C-E in the Results section:</p><p>“Additionally, we examined the relationship between estimation uncertainty and observation uncertainty in a number of edge cases where IC<sub>50</sub> was estimated within and beyond the maximum concentration tested (Figure 2C-E).”</p><p>The reviewer noted that it may not be correct to impose monotonicity when IC<sub>50</sub> might fall outside the measured range, so we showed that there is much greater IC<sub>50</sub> uncertainty in those cases. For clarifying this and enhancing the visualisation, we display curve fits within concentration range in solid lines, whilst less confident fits exceeding max concentration are indicated in grey. Furthermore, we have added in red horizontal lines showing the IC<sub>50</sub> confidence intervals, which are much larger outside of concentration range. We have also provided more rationale and guidance in the Discussion section for interpreting IC<sub>50</sub>s at untested concentrations:</p><p>“However, extrapolating beyond the concentration range would be challenging due to the uncertainty in the behaviour of the dose-response curve in unobserved concentrations. […] Instead, our method defines a very large confidence interval for drug response statistics extrapolated beyond the maximum dose tested and we would additionally need to take the observation uncertainty between replicate experiments into account.”</p><disp-quote content-type="editor-comment"><p>4) Additional model checking and comparisons would be useful. For example, Comparing the presented models to a more standard sigmoid, and additional comparisons highlighted in the comments.</p></disp-quote><p>We thank the reviewer for this insightful comment. In order to address this, we have performed a within drug random bootstrap sampling of 80% of all treated cell lines for the Sigmoid model. In particular, we estimated the uncertainty of the model for the drugs dabrafenib and lenalidomide for colorectal and melanoma cell lines, respectively (new Figure 5—figure supplement 1), to compare with GP’s variance estimation (Figure 5B-C). As theorized, the incorporation of uncertainty in the GP model provides a more adequate variance estimation in the prediction of non-responding cell lines IC<sub>50</sub>’s.</p><p>An explanation of the methodology was added in the Materials and methods section:</p><p>“To estimate the uncertainty of the Sigmoid curve fitting, a random bootstrap sampling of 80% of all treated cell lines available for each drug over 100 iterations was performed. […] The standard deviation of the log(IC<sub>50</sub>) estimates was computed to assess the model’s variance.”</p><p>Additionally, a comparison between the models was added in the Results section:</p><p>“Additionally, a comparison of the uncertainty estimates for the GP and the Sigmoid curve fitting methods revealed that both display concordant results (Figure 5B and C; Figure 5—figure supplement 1); However, the Sigmoid curve fitting method (Materials and methods; Vis et al., 2013) underestimates variance of non-responding cell lines rendering the GP approach superior.”</p><disp-quote content-type="editor-comment"><p>It would also help to clarify the relationship between Bayesian posterior probabilities, and ANOVA q-values for the GP approach.</p></disp-quote><p>We agree with the reviewer that Bayesian posterior probabilities and ANOVA q-values are different statistical quantities that should not be compared in absolute terms. Posterior probabilities capture the properties of the distribution of a parameter treated as a random value; q-values make a statement about the probability of observing an estimated (fixed) parameter value under the null hypothesis. Nevertheless, we believe that our comparison of these quantities, in relative terms, is valid, because we are interested in the value of using each of them for making a decision about the association between drug sensitivity and biomarkers. ANOVA q-values represent the state of the art, which means that we would expect a broad correlation between the q-values and the Bayesian posterior probabilities, with some deviations in cases where the inclusion of uncertainty estimates helps the Bayesian model detect or discard associations. This is what we see in Figure 5A, which displayed agreement between both statistical quantities and disagreements for a few biomarker associations. The key observation here is that the comparison is in terms of the relative ranking of the Bayesian posterior probabilities and ANOVA q-values, respectively, which enabled us to draw concordant conclusions in terms of prioritising biomarkers of drug response for clinical testing.</p><p>We have now added clarifying text in the Results section:</p><p>“Since both Bayesian and frequentist methods can be used to prioritise biomarkers for further testing, we compared association statistics (posterior probabilities and q-values) from both statistical methods.”</p><p>And the Discussion section:</p><p>“While Bayesian posterior probabilities and ANOVA q-values are different statistical quantities for measuring biomarker associations that should not be compared in absolute terms, we compared these quantities in relative terms to prioritise biomarkers of response for further testing.”</p><disp-quote content-type="editor-comment"><p>5) The authors should revise Figure 3C and D. Grouping response curves by mechanism can be misleading since different drugs or biomarkers may intrinsically have discordant potencies due to differing on-target binding efficiency or off-target effects.</p></disp-quote><p>Thank you for touching upon an important point about possible off-targets. While we have information on the primary targets of the drugs, off-targets effects are difficult to measure and define, especially with the histone chromatin targeting drugs we highlighted. Therefore, we classified the target pathways into broad categories that can include many possible target genes (e.g. histone methylation, mitosis). Nevertheless, we have edited the Results and Discussion sections to acknowledge off-target effects as a possible reason for the observed uncertainties. We have also added Figure 3E to show the distribution of uncertainties for individual drugs within the pathways we highlighted and not mislead by grouping drugs. It was reassuring to see that the distributions for individual drugs recapitulate what was seen when we aggregated the drugs into target pathways.</p></body></sub-article></article>